CN116143757A - 一种可降解btk激酶的多功能化合物、组合物及应用 - Google Patents
一种可降解btk激酶的多功能化合物、组合物及应用 Download PDFInfo
- Publication number
- CN116143757A CN116143757A CN202211467110.XA CN202211467110A CN116143757A CN 116143757 A CN116143757 A CN 116143757A CN 202211467110 A CN202211467110 A CN 202211467110A CN 116143757 A CN116143757 A CN 116143757A
- Authority
- CN
- China
- Prior art keywords
- amino
- piperidin
- alkyl
- cycloalkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 title description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 13
- 229940002612 prodrug Drugs 0.000 claims abstract description 11
- 239000000651 prodrug Substances 0.000 claims abstract description 11
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 10
- 230000005764 inhibitory process Effects 0.000 claims abstract description 9
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims abstract description 8
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims abstract description 8
- 208000035475 disorder Diseases 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000002062 proliferating effect Effects 0.000 claims abstract description 6
- 210000004180 plasmocyte Anatomy 0.000 claims abstract description 5
- 230000008901 benefit Effects 0.000 claims abstract description 3
- -1 C 1 -C 4 Alkylamino Chemical group 0.000 claims description 324
- 125000000217 alkyl group Chemical group 0.000 claims description 73
- 125000001424 substituent group Chemical group 0.000 claims description 53
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 47
- 125000003545 alkoxy group Chemical group 0.000 claims description 46
- 125000000623 heterocyclic group Chemical group 0.000 claims description 42
- 125000003118 aryl group Chemical group 0.000 claims description 41
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 38
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- 125000003282 alkyl amino group Chemical group 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 229910003827 NRaRb Inorganic materials 0.000 claims description 30
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 27
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 25
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000001188 haloalkyl group Chemical group 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000000126 substance Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000028622 Immune thrombocytopenia Diseases 0.000 claims description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 150000001345 alkine derivatives Chemical class 0.000 claims description 3
- 208000017760 chronic graft versus host disease Diseases 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims description 2
- 206010009346 Clonus Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000002033 Myoclonus Diseases 0.000 claims description 2
- 208000003435 Optic Neuritis Diseases 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 201000002661 Spondylitis Diseases 0.000 claims description 2
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims description 2
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 125000003636 chemical group Chemical group 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 150000001924 cycloalkanes Chemical class 0.000 claims description 2
- 150000001925 cycloalkenes Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 201000003444 follicular lymphoma Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 210000001165 lymph node Anatomy 0.000 claims description 2
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 2
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims description 2
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 230000001537 neural effect Effects 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 2
- 206010043207 temporal arteritis Diseases 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000024869 Goodpasture syndrome Diseases 0.000 claims 1
- 201000003791 MALT lymphoma Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 206010071990 Tyrosine kinase mutation Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 12
- 238000006731 degradation reaction Methods 0.000 abstract description 12
- 238000010521 absorption reaction Methods 0.000 abstract description 8
- 230000004663 cell proliferation Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 210000004185 liver Anatomy 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 3
- 230000004060 metabolic process Effects 0.000 abstract description 2
- 239000011859 microparticle Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 79
- 238000006243 chemical reaction Methods 0.000 description 73
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 60
- 239000007787 solid Substances 0.000 description 42
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 40
- 125000005843 halogen group Chemical group 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 33
- 239000012074 organic phase Substances 0.000 description 33
- 238000004440 column chromatography Methods 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- 230000002194 synthesizing effect Effects 0.000 description 28
- 230000015572 biosynthetic process Effects 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 23
- 125000003003 spiro group Chemical group 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- 125000003368 amide group Chemical group 0.000 description 14
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 13
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 13
- 238000010791 quenching Methods 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 11
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 125000000392 cycloalkenyl group Chemical group 0.000 description 10
- 229910052805 deuterium Inorganic materials 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 9
- 125000004414 alkyl thio group Chemical group 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000010828 elution Methods 0.000 description 9
- 229940124530 sulfonamide Drugs 0.000 description 9
- 150000003456 sulfonamides Chemical class 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 150000007942 carboxylates Chemical class 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 230000000171 quenching effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 241001024304 Mino Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000011737 fluorine Substances 0.000 description 5
- 125000003367 polycyclic group Chemical group 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- RPABADYMEMUBEC-UHFFFAOYSA-N 1-oxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC11OCCC1 RPABADYMEMUBEC-UHFFFAOYSA-N 0.000 description 4
- MPQLCQKBYRSPNA-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5-fluoroisoindole-1,3-dione Chemical compound O=C1C2=CC(F)=CC=C2C(=O)N1C1CCC(=O)NC1=O MPQLCQKBYRSPNA-UHFFFAOYSA-N 0.000 description 4
- PVYCHTWXOPDNCE-UHFFFAOYSA-N 4-(1,3-dioxolan-2-yl)piperidine Chemical compound O1CCOC1C1CCNCC1 PVYCHTWXOPDNCE-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- HHEIMYAXCOIQCJ-UHFFFAOYSA-N ethyl 2,2-dimethylpropanoate Chemical compound CCOC(=O)C(C)(C)C HHEIMYAXCOIQCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 108091008875 B cell receptors Proteins 0.000 description 3
- 229940124291 BTK inhibitor Drugs 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000032825 Ring chromosome 2 syndrome Diseases 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 239000012300 argon atmosphere Substances 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006837 decompression Effects 0.000 description 3
- WXJHHRMJGBPYEG-UHFFFAOYSA-N ethyl 5-chloro-3-methylsulfanyl-1,2,4-triazine-6-carboxylate Chemical compound CCOC(=O)C1=NN=C(SC)N=C1Cl WXJHHRMJGBPYEG-UHFFFAOYSA-N 0.000 description 3
- 125000005347 halocycloalkyl group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- UEXQBEVWFZKHNB-UHFFFAOYSA-N intermediate 29 Natural products C1=CC(N)=CC=C1NC1=NC=CC=N1 UEXQBEVWFZKHNB-UHFFFAOYSA-N 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- CNMFHDIDIMZHKY-UHFFFAOYSA-N methyl 2,2-dimethylpropanoate Chemical compound COC(=O)C(C)(C)C CNMFHDIDIMZHKY-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
- JAEIBKXSIXOLOL-UHFFFAOYSA-N pyrrolidin-1-ium-3-carboxylate Chemical compound OC(=O)C1CCNC1 JAEIBKXSIXOLOL-UHFFFAOYSA-N 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- IRYIEVNNJRRABT-SNVBAGLBSA-N tert-butyl (3r)-3-acetamidopiperidine-1-carboxylate Chemical compound CC(=O)N[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 IRYIEVNNJRRABT-SNVBAGLBSA-N 0.000 description 3
- CIXGRHBBERZOAY-UHFFFAOYSA-N 1-(2-fluoro-4-nitrophenyl)piperidine-4-carbaldehyde Chemical compound FC1=CC([N+](=O)[O-])=CC=C1N1CCC(C=O)CC1 CIXGRHBBERZOAY-UHFFFAOYSA-N 0.000 description 2
- QBQRRWPLTOBGST-UHFFFAOYSA-N 1-(4-bromophenyl)-1,3-diazinane-2,4-dione Chemical compound C1=CC(Br)=CC=C1N1C(=O)NC(=O)CC1 QBQRRWPLTOBGST-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- HVBSAKJJOYLTQU-UHFFFAOYSA-N 4-aminobenzenesulfonic acid Chemical compound NC1=CC=C(S(O)(=O)=O)C=C1 HVBSAKJJOYLTQU-UHFFFAOYSA-N 0.000 description 2
- NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- FSLAXEXHFAZCDZ-UHFFFAOYSA-N O1C(OCC1)C1CCN(CC1)C=1C=CC(=NC=1)C(=O)O Chemical compound O1C(OCC1)C1CCN(CC1)C=1C=CC(=NC=1)C(=O)O FSLAXEXHFAZCDZ-UHFFFAOYSA-N 0.000 description 2
- MOIIHCSYWHNTCG-UHFFFAOYSA-N O=C(CCN1C(C=CC(N(CC2)CCC2C2OCCO2)=C2)=C2F)NC1=O Chemical compound O=C(CCN1C(C=CC(N(CC2)CCC2C2OCCO2)=C2)=C2F)NC1=O MOIIHCSYWHNTCG-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- SYZMMRYQYWCLNC-UHFFFAOYSA-N [6-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]pyridin-3-yl]boronic acid Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(B(O)O)C=N1 SYZMMRYQYWCLNC-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000004992 haloalkylamino group Chemical group 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- CEMZBWPSKYISTN-YFKPBYRVSA-N methyl (2s)-2-amino-3-methylbutanoate Chemical compound COC(=O)[C@@H](N)C(C)C CEMZBWPSKYISTN-YFKPBYRVSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BCXSCZDWARFWAW-SSDOTTSWSA-N n-[(3r)-piperidin-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1CCCNC1 BCXSCZDWARFWAW-SSDOTTSWSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- DWLADVOODHZCFV-UHFFFAOYSA-N tert-butyl 3-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)C1 DWLADVOODHZCFV-UHFFFAOYSA-N 0.000 description 2
- JYTFREFXHAFMQV-UHFFFAOYSA-N tert-butyl 4-(4-amino-2-fluorophenyl)piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(N)C=C1F JYTFREFXHAFMQV-UHFFFAOYSA-N 0.000 description 2
- JYUQEWCJWDGCRX-UHFFFAOYSA-N tert-butyl 4-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C=O)CC1 JYUQEWCJWDGCRX-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical group C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- 125000006025 1-methyl-1-butenyl group Chemical group 0.000 description 1
- 125000006044 1-methyl-1-pentenyl group Chemical group 0.000 description 1
- 125000006028 1-methyl-2-butenyl group Chemical group 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- RPEPGIOVXBBUMJ-UHFFFAOYSA-N 2,3-difluorophenol Chemical compound OC1=CC=CC(F)=C1F RPEPGIOVXBBUMJ-UHFFFAOYSA-N 0.000 description 1
- RJXOVESYJFXCGI-UHFFFAOYSA-N 2,4-difluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1F RJXOVESYJFXCGI-UHFFFAOYSA-N 0.000 description 1
- AGHXYRKTAZEQQW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-5,6-difluoroisoindole-1,3-dione Chemical group O=C1C=2C=C(F)C(F)=CC=2C(=O)N1C1CCC(=O)NC1=O AGHXYRKTAZEQQW-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000006045 2-methyl-1-pentenyl group Chemical group 0.000 description 1
- OQHQOOLVQDEIGL-UHFFFAOYSA-N 2-methyl-2,7-diazaspiro[4.4]nonane Chemical compound C1N(C)CCC11CNCC1 OQHQOOLVQDEIGL-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- GUSWJGOYDXFJSI-UHFFFAOYSA-N 3,6-dichloropyridazine Chemical compound ClC1=CC=C(Cl)N=N1 GUSWJGOYDXFJSI-UHFFFAOYSA-N 0.000 description 1
- MRQMMZRTPYMDPW-UHFFFAOYSA-N 3-(4-bromoanilino)propanoic acid Chemical compound OC(=O)CCNC1=CC=C(Br)C=C1 MRQMMZRTPYMDPW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BHPOOUUMRGOCIR-UHFFFAOYSA-N 3-bromo-2,6-bis(phenylmethoxy)pyridine Chemical compound N1=C(OCC=2C=CC=CC=2)C(Br)=CC=C1OCC1=CC=CC=C1 BHPOOUUMRGOCIR-UHFFFAOYSA-N 0.000 description 1
- RYSICGXZRVMXDP-UHFFFAOYSA-N 3-bromopiperidine-2,6-dione Chemical compound BrC1CCC(=O)NC1=O RYSICGXZRVMXDP-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- OFDVABAUFQJWEZ-UHFFFAOYSA-N 3-pyridin-3-ylpyridine Chemical compound C1=CN=CC(C=2C=NC=CC=2)=C1 OFDVABAUFQJWEZ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WDFQBORIUYODSI-UHFFFAOYSA-N 4-bromoaniline Chemical compound NC1=CC=C(Br)C=C1 WDFQBORIUYODSI-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- KPIJBKHHJXXREK-UHFFFAOYSA-N 5-bromo-2-chloro-3-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC(Br)=CN=C1Cl KPIJBKHHJXXREK-UHFFFAOYSA-N 0.000 description 1
- PEDMFCHWOVJDNW-UHFFFAOYSA-N 5-fluoro-2-nitroaniline Chemical compound NC1=CC(F)=CC=C1[N+]([O-])=O PEDMFCHWOVJDNW-UHFFFAOYSA-N 0.000 description 1
- CGFYNRVHPARGFY-UHFFFAOYSA-N 5-fluoro-2-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(F)C=N1 CGFYNRVHPARGFY-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-AHCXROLUSA-N Bromine-79 Chemical compound [76Br] WKBOTKDWSSQWDR-AHCXROLUSA-N 0.000 description 1
- SBCFJKABENIUEE-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C=C1)=NC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C=C1)=NC=C1C(C(OCC1=CC=CC=C1)=N1)=CC=C1OCC1=CC=CC=C1)=O SBCFJKABENIUEE-UHFFFAOYSA-N 0.000 description 1
- UPEHZSAUMXGHSJ-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C1=NC=C(C(CCC(N2)=O)C2=O)C=C1)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C1=NC=C(C(CCC(N2)=O)C2=O)C=C1)=O UPEHZSAUMXGHSJ-UHFFFAOYSA-N 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-IGMARMGPSA-N Carbon-12 Chemical compound [12C] OKTJSMMVPCPJKN-IGMARMGPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 102000009438 IgE Receptors Human genes 0.000 description 1
- 108010073816 IgE Receptors Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- YHBNWRDHXHZBCH-UHFFFAOYSA-N NC(C=CC(N(CC1)CCC1C1OCCO1)=C1)=C1F Chemical compound NC(C=CC(N(CC1)CCC1C1OCCO1)=C1)=C1F YHBNWRDHXHZBCH-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- QPQVCBBAMMKCNJ-UHFFFAOYSA-N O=CC(CC1)CCN1C(C=C1)=CC(F)=C1N(CCC(N1)=O)C1=O Chemical compound O=CC(CC1)CCN1C(C=C1)=CC(F)=C1N(CCC(N1)=O)C1=O QPQVCBBAMMKCNJ-UHFFFAOYSA-N 0.000 description 1
- 239000012270 PD-1 inhibitor Substances 0.000 description 1
- 239000012668 PD-1-inhibitor Substances 0.000 description 1
- 239000012271 PD-L1 inhibitor Substances 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000003728 Vulvodynia Diseases 0.000 description 1
- 206010069055 Vulvovaginal pain Diseases 0.000 description 1
- TZAQBTSGIKWDRO-UHFFFAOYSA-N [O-][N+](C(C=CC(N(CC1)CCC1C1OCCO1)=C1)=C1F)=O Chemical compound [O-][N+](C(C=CC(N(CC1)CCC1C1OCCO1)=C1)=C1F)=O TZAQBTSGIKWDRO-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZOAIGCHJWKDIPJ-UHFFFAOYSA-M caesium acetate Chemical compound [Cs+].CC([O-])=O ZOAIGCHJWKDIPJ-UHFFFAOYSA-M 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- VEXZGXHMUGYJMC-IGMARMGPSA-N chlorine-35 Chemical compound [35ClH] VEXZGXHMUGYJMC-IGMARMGPSA-N 0.000 description 1
- GGRHYQCXXYLUTL-UHFFFAOYSA-N chloromethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCCl GGRHYQCXXYLUTL-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- HPNSNYBUADCFDR-UHFFFAOYSA-N chromafenozide Chemical compound CC1=CC(C)=CC(C(=O)N(NC(=O)C=2C(=C3CCCOC3=CC=2)C)C(C)(C)C)=C1 HPNSNYBUADCFDR-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- KCMBKUFSDZMQEM-UHFFFAOYSA-N methyl 5-fluoropyridine-2-carboxylate Chemical compound COC(=O)C1=CC=C(F)C=N1 KCMBKUFSDZMQEM-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000005244 neohexyl group Chemical group [H]C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QXAHJILNWYDAIV-UHFFFAOYSA-N o-ethyl 4-chloro-2-methylpyrimidine-5-carbothioate Chemical compound CCOC(=S)C1=CN=C(C)N=C1Cl QXAHJILNWYDAIV-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940121655 pd-1 inhibitor Drugs 0.000 description 1
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- HRVXPXCISZSDCC-UHFFFAOYSA-N piperidine-4-carbaldehyde Chemical compound O=CC1CCNCC1 HRVXPXCISZSDCC-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 229950000244 sulfanilic acid Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- NINIDFKCEFEMDL-IGMARMGPSA-N sulfur-32 atom Chemical compound [32S] NINIDFKCEFEMDL-IGMARMGPSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 1
- YRLQFRXDWBFGMK-UHFFFAOYSA-N tert-butyl 4-(4-aminophenyl)piperidine-1-carboxylate Chemical group C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=C(N)C=C1 YRLQFRXDWBFGMK-UHFFFAOYSA-N 0.000 description 1
- DSLVSFMWCDGZIL-UHFFFAOYSA-N tert-butyl 4-(5-bromopyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=C(Br)C=N1 DSLVSFMWCDGZIL-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-MRVPVSSYSA-N tert-butyl n-[(3r)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCNC1 WUOQXNWMYLFAHT-MRVPVSSYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000006337 tetrafluoro ethyl group Chemical group 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- WUOFQGMXQCSPPV-UHFFFAOYSA-N tributyl(1,3-thiazol-2-yl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C1=NC=CS1 WUOFQGMXQCSPPV-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Abstract
本发明公开了一种布鲁顿酪氨酸激酶降解剂,其具有通式I的结构;或其立体异构体,或其立体异构体混合物,或其药学上可接受的盐、前药;还公开了该化合物以及包含该化合物的药物组合物在制备治疗与布鲁顿酪氨酸激酶相关疾病如B细胞或浆细胞增殖性疾病。本发明的化合物具有强效的细胞增殖抑制活性,有效降解布鲁顿酪氨酸激酶,肝微粒代谢稳定性好,较好的口服吸收性质。可应用于在单独或与其他药物联合应用治疗从布鲁顿酪氨酸激酶活性的抑制或降解中获益的疾病、障碍或病症药物中的应用。
Description
技术领域
本发明属于医药合成技术领域,具体是涉及一种可降解BTK激酶的多功能化合物、组合物及应用。
背景技术
布鲁顿氏酪氨酸激酶BTK作为Tec蛋白家族中的一员(BTK,Tec,Txk,Itk&Bmx),是在除了T淋巴细胞之外的所有造血细胞类型中表达的关键信号酶,主要表达在B淋巴细胞中,BTK在连接细胞表面B细胞受体(B-cell receptor,BCR)刺激至下游细胞内应答的B细胞信号传导途径中扮演至关重要的角色,已被临床证实为重要的药物靶标。BTK是B细胞发育、激活、信号传导和存活的关键调节物。另外,BTK在众多其他造血细胞信号传导途径中起作用,例如在巨噬细胞中的Toll样受体(Toll like receptor,TLR)和细胞因子受体介导的TNF-α产生、在肥大细胞中的免疫球蛋白E受体(FcεR1)信号传导、在B-谱系淋巴样细胞中抑制Fas/APO-1细胞凋亡的信号传导以及胶原刺激的血小板聚集。参见例如C.A.Jeffries等,J.Bio.Chem.(2003)278:26258-26264、N.J.Horwood等,J.Exp.Med.(2003)197:1603-1611。近年来研究显示,BTK信号通路是目前非霍奇金淋巴瘤(NHL),特别是慢性淋巴细胞白血病(CLL)、B细胞淋巴瘤及自身免疫疾病临床治疗研究中的新热点。小分子BTK抑制剂通过作用于BCR信号通路,与BTK结合而抑制BTK自身磷酸化,阻止BTK的激活,从而阻断细胞传导并诱导细胞凋亡。
随着共价BTK抑制在临床上的使用,部分CLL患者已经出现BTK C481突变,而造成的BTK药物获得性耐药问题,亟需新一代BTK药物解决这一获得性耐药。
靶向蛋白降解嵌合分子(PROTAC)技术取得了重大的进展,该技术通过其通过泛素-蛋白酶体系统诱导致癌蛋白泛素化从而被降解。采用该技术的药物,无需持续占据靶蛋白,催化浓度即可实现靶点降解。因此开发针对BTK的靶向降解分子,有望解决BTK获得性耐药问题。
发明内容
本发明的目的是提供新颖的、未见文献报道的具有BTK降解活性,并具有优良口服PK性质优良的布鲁顿氏酪氨酸激酶BTK降解剂或其光学异构体、立体异构体、或其立体异构体混合物,或其药学上可接受的盐或溶剂合物,前药,以及在BTK相关疾病B细胞或浆细胞增殖性疾病和自身免疫性疾病中的用途。
本发明的第一方面,提供了如式I所示的化合物,或其药学上可接受的盐,前药;
其中:
L选自:连接环A和E3的化学基团和化学键;
E3选自:E3泛素连接酶配体;
环A选自:3-12元杂环、6-10元芳环、5-12元杂芳环,3-12元环烷、4-12元环炔、3-12元环烯,其中所述的杂环、杂芳环具有1-3个独立选自N、O或S的杂原子;
R2选自:H、卤素、氰基、C1-C6烷基、C1-C6卤代烷基、C3-C8环烷基、C1-C4烷氧基、C3-C8环烷氧基、C3-C8杂环基、C1-C4烷氨基、-COOH、-NH2、OH、NO2;
n选自:0、1、2、3、4;
Y1选自:N,CR4;
Y2选自:N,CR5;
Y3选自:N,CR5;
R4选自:卤素、C1-C4烷基、C3-C8环烷基、C1-C4卤代烷基、C3-C8卤代环烷基、C1-C4烷氧基、氨基、羧基、羟基、氰基;
R5选自:H、卤素、C1-C4烷基、C3-C8环烷基、C1-C4卤代烷基、C3-C8卤代环烷基、C1-C4烷氧基、氨基、羧基、羟基、氰基;
R3选自:H、C1-C8烷基、C1-C6卤代烷基、C3-C8烯烃、C3-C8炔烃、环烷基、杂环基、芳基;
R1选自:NR6R7、OR6、SR6、-C(O)R6、-C(O)OR6、-C(O)NR6R7、OC(O)R6、OC(O)NR6R7、S(O)R6、S(O)(=NH)R6、S(O)2NR6R7、N(R6)C(O)R7、N(R6)C(O)OR7、C1-C8烷基、3-12元杂环、5-6元杂芳环、C3-C8环烷基、芳环基,其中所述的烷基、杂环、杂芳环、环烷基、芳环基可进一步被一个或者多个选自R8的取代基取代;
R8选自:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;其中所述的烷基、烷氧基、环烷基可进一步被一个或者多个取代基取代,取代基包括:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基;
R6、R7各自独立的选自H、C1-C8烷基、胺烷基、羟烷基、C3-C8环烷基、杂环基、芳环基、杂芳基;所述的烷基、胺烷基、羟烷基、环烷基、杂环基、芳环基、杂芳基可进一步被一个或者多个取代基取代,取代基包括H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;
Ra、Rb、Rc各自独立的选自H、卤素、烷基、氨基、羟基、氰基、C3-C8环烷基、烷氨基、烷氧基。
Y2、Y3同时选择CR5时,两个取代中R5相互独立,可以相同,也可以不相同。
作为优选,Y1、Y2、Y3同时为N。
进一步地,本发明优选的化合物:
环A选自:6-10元芳环、5-12元杂芳环;其中所述的杂环、杂芳环具有1-3个独立选自N、O或S的杂原子,其中:
进一步地,本发明优选的化合物具有通式II(a)~II(i)的结构:
或其立体异构体,或其立体异构体混合物,或其药学上可接受的盐,前药。
进一步,本发明优选的化合物具有通式III(a)-III(c)的结构:
或其立体异构体,或其立体异构体混合物,或其药学上可接受的盐,前药;
R1优选自:NR6R7、OR6、C1-C8烷基、3-12元杂环、5-6元杂芳环、C3-C8环烷基、芳环基;其中所述的烷基、杂环、杂芳环、环烷基、芳环基可进一步被一个或者多个选自R8的取代基取代;
R8优选自:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;其中所述的烷基、烷氧基、环烷基可进一步被一个或者多个取代基取代,取代基包括:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基;
R6、R7优选自:H、C1-C8烷基、胺烷基、羟烷基、C3-C8环烷基、杂环基、芳环基、杂芳基;所述的烷基、胺烷基、羟烷基、环烷基、杂环基、芳环基、杂芳基可进一步被一个或者多个取代基取代,取代基包括H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;
Ra、Rb、Rc各自独立的优选自H、卤素、烷基、氨基、羟基、氰基、C3-C8环烷基、烷氨基、烷氧基。
在一些实施方案中,R2的优选为:H、F。
在一些实施方案中,R1优选自:
更一步地,作为优选方案:
L优选自:
E3选自:
Re选自:H、F、Cl、-CH3、-OMe、-CN、-CF3;
Rd选自:H、L2Rg;
R9选自:H、C1-C5烷基(优选为甲基、);
q选自:1、2、3、4或5;
Rg选自:H、C1-C8烷基、取代的C1-C8烷基(优选为叔丁基、异丁基等);取代基选自氨基、羟基、氰基、卤素。
更一步地,E3选自:
作为优选,所述的化合物或其立体异构体或其立体异构体混合物或其药学上可接受的盐,前药,选自下列化合物:
或其立体异构体或其立体异构体混合物或其药学上可接受的盐、前药。作为优选,所述化合物为如下化合物:
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺001
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺002
5-((4-(4-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺003
5-((6-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)哒嗪-3-基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺004
5-((2-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)嘧啶-5-基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺005
5-((4-(4-((1-(2-(2,6-d二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)氮杂环丁烷-3-基)甲基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺006
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌啶-4-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺007
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)氮杂环丁烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-羧酰胺008
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-羧酰胺009
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-6-氟-1-氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺010
5-((4-(1-((1-(1-(2,6-二氧代哌啶-3-基)-3-甲基-2-氧代-2,3-二氢-1H-苯并[d]咪唑-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺011
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1-氧代-1,2-二氢异喹啉-6-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺012
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1-氧代-1,2,3,4-四氢异喹啉-6-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺013
5-((4-(1-((1-(5-((2,6-二氧代哌啶-3-基)氨基)吡啶-2-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺014
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-((R)-3-羟基哌啶-1-基)-1,2,4-三嗪-6-甲酰胺015
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺016
3-(((S)-1-氨基-1-氧代丁烷-2-基)氨基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺017
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-6-甲酰胺018
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-吗啉代-1,2,4-三嗪-6-甲酰胺019
3-((3-氰基苯基)氨基)-5-((4-(1-((1-((2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺020
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(吡啶-2-基氨基)-1,2,4-三嗪-6-甲酰胺021
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-((R)-3-羟基吡咯烷-1-基)-1,2,4-三嗪-6-甲酰胺022
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌啶-4-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺023
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(噻唑-2-基)-1,2,4-三嗪-6-甲酰胺024
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(1H-咪唑-2-基)-1,2,4-三嗪-6-甲酰胺025
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(吡啶-3-基)-1,2,4-三嗪-6-甲酰胺026
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(3-羟基苯氧基)-1,2,4-三嗪-6-甲酰胺027
3-(2,3-二氟苯氧基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺028
3-((R)-3-氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺029
3-(((1S,2R)-2-氨基环己基)氨基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺030
5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌嗪-1-基)-1,2,4-三嗪-6-甲酰胺031
2-(((1S,2R)-2-氨基环己基)氨基)-4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)嘧啶-5-甲酰胺032
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-2-(哌啶-1-基)嘧啶-5-甲酰胺033
4-((4-(4-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-2-(哌啶-1-基)嘧啶-5-甲酰胺034
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-2-((R)-3-羟基哌啶-1-基)嘧啶-5-甲酰胺035
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-2-(哌啶-1-基)嘧啶-5-甲酰胺036
4-((4-(4-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-6-(哌啶-1-基)烟酰胺037
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-(哌啶-1-基)烟酰胺038
3-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-甲基-5-(哌啶-1-基)吡嗪-2-甲酰胺039
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-(哌啶-1-基)哒嗪-3-甲酰胺040
4-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-((R)-3-羟基哌啶-1-基)哒嗪-3-甲酰胺041
3-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-氟-5-(哌啶-1-基)吡嗪-2-甲酰胺042
3-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-6-甲氧基-5-(哌啶-1-基)吡嗪-2-甲酰胺043
5-((4-(4-((4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺044
5-((4-(4-((4-(2-(2,6-二氧代哌啶-3-基)-6-氟-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺045
5-((4-(4-((4-(2-(2,6-二氧代哌啶-3-基)-6-氟-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)哌啶-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺046
5-((6-(4-((4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-基)甲基)哌啶-1-基)吡啶-3-基)氨基)-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-6-甲酰胺047
5-((6-(4-((4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-基)甲基)哌啶-1-基)吡啶-3-基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺048
5-((4-(3-((4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)氮杂环丁烷-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺049
5-((4-(4-((4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺050
4-((4-(4-((4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-2-(哌啶-1-基)嘧啶-5-甲酰胺051
5-((4-(4-((4-(4-(2,6-二氧代哌啶-3-基)苯基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺052
5-((4-(4-((4-(5-(2,6-二氧代哌啶-3-基)吡啶-2-基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺053
5-((4-(4-((4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-6-甲酰胺054
5-((4-(1-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-羰基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺055
5-((4-(4-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-羰基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺056
5-((4-(1-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌啶-4-羰基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺057
5-((4-(4-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌啶-4-羰基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺058
5-((4-(1-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)氮杂环丁烷-3-羰基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺059
5-((4-(4-(4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-羰基)哌啶-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺060
5-((4-(4-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)氮杂环丁烷-3-羰基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺061
(3-(5-(3-((4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯062
(3-(5-(3-((4-(4-((6-氨基甲酰基-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯063
(3-(5-(3-((4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌嗪-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯064
(3-(5-(3-((4-(4-((5-氨基甲酰基-2-(哌啶-1-基)嘧啶-4-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯065
(3-(4-(4-((1-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)苯基)-2,6-二氧代四氢嘧啶-1(2H)-基)新戊酸甲酯066
5-((4-(1-((1-(2-(二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-((R)-3-羟基哌啶-1-基)-1,2,4-三嗪-6-甲酰胺067
(3-(5-(3-((4-(4-((6-氨甲酰-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯068
1-(3-(5-(3-((4-(4-((6-氨甲酰-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸乙酯069
1-(3-(5-(3-((4-(4-((6-氨甲酰-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸乙酯070
1-(3-(5-(3-((4-(4-((6-氨甲酰-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌嗪-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸乙酯071
1-(3-(5-(3-((4-(4-((6-氨甲酰-3-(4-甲基哌嗪-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸乙酯072
(3-(5-(3-((4-(4-((6-氨甲酰-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)L-缬氨酸甲酯073
(3-(5-(3-((4-(4-((6-氨甲酰-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌嗪-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)L-缬氨酸甲酯074
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺075
5-((4-(4-((4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺076
5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺077
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺078
5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基甲酰基)吡啶-3-基)吡咯烷-3-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺079
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺080
5-((3-氟-4-(4-((1-(5-(6-氧代-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺081
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲氧基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺082
5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基甲酰基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺083
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-2-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺084
5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基甲酰基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺085
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-2-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺086
5-((3-氟-4-(4-((1-(4-(6-氧代-1,6-二氢哒嗪-3-基)-2-(三氟甲基)苯基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺087
5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺088
5-((3-氟-4-(4-((4-(4-(6-氧代-1,6-二氢哒嗪-3-基)-2-(三氟甲基)苯基)哌嗪-1-基)甲基)哌啶-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺089
(R)-3-(3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺090
(R)-3-(3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺091
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基甲酰基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺092
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基甲酰基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺093
(R)-3-(3-乙酰氨基哌啶-1-基)-5-((3-氟-4-(4-((1-(5-(6-氧代-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺094
(R)-3-(3-乙酰氨基哌啶-1-基)-5-((3-氟-4-(4-((1-(4-(6-氧代-1,6-二氢哒嗪-3-基)-2-(三氟甲基)苯基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺095
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺096
3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺097
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺098
5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺099
5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基甲酰基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺100
5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基甲酰基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺101
5-((3-氟-4-(4-((1-(5-(6-氧代-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺102
5-((3-氟-4-(4-((1-(4-(6-氧代-1,6-二氢哒嗪-3-基)-2-(三氟甲基)苯基)哌啶-4-基)甲基)哌嗪-1-基)苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺103
5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺104
5-((4-(4-((1-(4-((2,6-二氧代哌啶-3-基)氨基)-3-氟苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-吗啉基-1,2,4-三嗪-6-甲酰胺105
术语说明
除非另有定义,本发明使用的所有技术和科学术语与该领域专业人员通常理解的含义相同。除非另有说明,本发明参考的所有专利文献、公开披露的资料等全文纳入参考文献。如本发明中同一术语有多个定义,以本节中的定义为准。
需要理解的是,前文的一般描述和后文的详细描述仅仅是示范性的和解释性的,对任何权利要求都无限制性。在本发明中,除非另有说明,使用的单数包含复数。需要注意的是,说明书和所附权利要求书中,除非文中另有说明,单数形式指代如“一”、“一个”、“这个”,包含复数指代。还需注意的是,除非另有说明,“或”代表“和/或”。此外,“包含”、“包括”等类似术语不是限制性的。
“取代”是指氢原子被取代基取代。需要注意的是,特定原子上的取代基是被其价态限制的。在定义部分,“Ci-j”是指包括起点和终点的范围,其中i和j都是整数,表示碳原子的数目。例如,C1-4,C1-10,C3-10等。
本发明所述基团和化合物中所涉及的C、H、O、S、N、F、Cl、Br、I等均包括它们的同位素情况。同时,本发明所述基团和化合物中所涉及的C、H、O、S、N、F、Cl、Br、I可任选的被一个或多个它们对应的同位素取代,包括但不限于碳的同位素12C、13C、14C,氢的同位素氕(H)、氘(D)、氚(T),氧的同位素16O、17O、18O,硫的同位素32S、33S、34S、36S,氮的同位素14N、15N,氟的同位素17F、19F,氯的同位素35Cl、37Cl,溴的同位素79Br、81Br等。
本发明所用术语“烷基”是指含有1至8个碳原子的直链或支链的饱和烃基,包括但不限于甲基、乙基、丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、正戊基、异戊基、新戊基、特戊基、正己基、异己基、新己基、庚烷基、异庚烷基、新庚烷基、辛基、异辛基等。烷基可被一个或者多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“烯基”“烯烃”是指含有1至8个碳原子且含至少一个C=C双键的直链或支链的烃链基团,包括但不限于乙烯基、1-丙烯基、2-丙烯基、1-丁烯基、2-丁烯基、3-丁烯基、1-戊烯基、2-戊烯基、3-戊烯基、4-戊烯基、1-甲基-1-丁烯基、1-甲基-2-丁烯基、1-己烯基、2-己烯基、3-己烯基、4-己烯基、5-己烯基、1-甲基-1-戊烯基、2-甲基-1-戊烯基、1-庚烯基、2-庚烯基、3-庚烯基、1-甲基-2-己烯基、2-甲基-2-己烯基、2-甲基-3-己烯基、3,5-二甲基-2-己烯基、3,3-二甲基-1-戊烯基、3-甲基-2-乙基-1-丁烯基、1-辛烯基、2-辛烯基等。烯基可被一个或者多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D、烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、卤代羟烷基、烷氨基、卤代烷氨基、环烷基、卤代环烷基、杂环基、芳基、杂芳基、羟基、卤素、氰基、硝基、氨基、氨基烷基、羧基、酰胺基、磺酰胺基、螺烷基。
本发明所用术语“炔基”“炔烃”是指含有1至8个碳原子且含至少一个C≡C叁键的直链或支链的烃链基团,包括但不限于乙炔基、1-丙炔基、2-丙炔基、1-丁炔基、2-丁炔基、3-丁炔基、1-戊炔基、2-戊炔基、3-戊炔基、4-戊炔基、3-甲基-1-丁炔基、4-甲基-1-丁炔基、2-甲基-3-丁炔基、1-甲基-4-丁炔基、1-己炔基、2-己炔基、3-己炔基、4-己炔基、1-甲基-2-戊炔基、1-甲基-3-戊炔基、1-甲基-4-戊炔基、2-甲基-3-戊炔基、2,2-二甲基-4-戊炔基、1-庚炔基、2-庚炔基、3-庚炔基、4-庚炔基、5-庚炔基、2-甲基-3-己炔基、3-甲基-1-己炔基、3,3-二甲基-1-己炔基、4-甲基-1-己炔基等。炔基可被一个或者多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D、烷基、卤代烷基、烷氧基、卤代烷氧基、羟烷基、卤代羟烷基、烷氨基、卤代烷氨基、环烷基、卤代环烷基、杂环基、芳基、杂芳基、羟基、卤素、氰基、硝基、氨基、氨基烷基、羧基、酰胺基、磺酰胺基、螺烷基。
本发明所用术语“环烷”“环烷基”是指具有3至12个碳原子的单环或多环(两个单环之间用化学键连接或桥环或螺环或稠合)的非芳香性单价烃基,且可有一个或多个化学键为双键或三键。“环烷基”包括但不限于环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基、环癸基、八氢茚、十氢萘、双环[1.1.0]丁烷基、双环[2.1.0]戊烷基、双环[2.2.0]己烷基、双环[3.2.0]庚烷基、双环[4.2.0]辛烷基、双环[1.1.1]戊烷基、双环[2.1.1]己烷基、双环[3.1.1]庚烷基、双环[2.2.1]庚烷基、双环[4.1.1]辛烷基、双环[3.2.1]辛烷基、双环[3.2.1]辛烷基、双环[5.1.1]壬烷基、双环[4.2.1]壬烷基、双环[4.3.1]壬烷基、双环[3.2.2]壬烷基、双环[5.2.1]癸烷基、双环[4.2.2]癸烷基、螺环[2.2]戊烷基、螺环[2.3]己烷基、螺环[2.4]庚烷基、螺环[2.5]辛烷基、螺环[2.6]壬烷基、螺环[3.5]壬烷基、螺环[3.4]辛烷基、螺环[3.3]庚烷基、螺环[4.5]癸烷基、螺环[4.4]壬烷基等。环烷基可被一个或多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“环烯”“环烯基”是指具有3至12个碳原子且至少含有一个C=C双键的单环或多环(两个单环之间用化学键连接或桥环或螺环或稠合)的非芳香性单价烃基,包括但不限于环丙烯基、环丁烯基、环戊烯基、环己烯基、环庚烯基、环烯基、螺[2.2]戊-1-烯基、螺[2.2]戊-1,4-二烯基、螺[2.3]己-1-烯基、螺[2.3]己-1,4-二烯基、螺[3.3]庚-1-烯基、螺[3.3]庚-1,5-二烯基、螺[3.4]辛-1-烯基、螺[3.4]辛-1,6-二烯基、螺[3.4]辛-5-烯基、螺[3.4]辛-6-烯基、螺[3.4]辛-1-烯基、双环[2.1.1]己-1-烯基、双环[2.1.1]己-2-烯基、双环[3.1.1]庚-1-烯基、双环[3.1.1]庚-2-烯基、双环[2.2.1]庚-1-烯基、双环[2.2.1]庚-2-烯基等。环烯、环烯基可被一个或多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C12杂芳基、C3-C12杂环基。
本发明所用术语“环炔”“环炔基”是指具有4个至12个碳原子的单环或多环(两个单环之间用化学键连接或桥环或螺环或稠合)的非芳香性烃基且至少含有一个三键,优选为环丁炔基、环戊炔基、环己炔基等,其中一个或两个碳原子可以由一个氧原子替代。该环炔基可以是无取代或取代的,其取代基选自D(氘)、氧代、卤素、氰基、硝基、羟基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C12杂芳基、C3-C12杂环基。
本发明所用术语“卤素”是指氟、氯、溴和碘,优选氟、氯或溴。
本发明所用术语“烷氧基”是指烷基-O-,其中烷基如上所定义。本发明所用“烷氧基”的实例包括但不限于甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、仲丁氧基、叔丁氧基、戊氧基、2-戊氧基、异戊氧基、新戊氧基、己氧基、2-己氧基、3-己氧基、3-甲基戊氧基等。“烷氧基”还包括取代烷氧基,其取代基可为D、卤素、氧代、氨基、羟基、氰基、硝基、羧基、酰胺基、磺酰胺基、螺烷基、C1-C8烷基、C1-C8羟烷基、C1-C8烷氧基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8羟烷基、卤代C1-C8烷氧基、卤代C1-C8烷氨基、C3-C12环烷基、C3-C12杂环基、C6-C12芳基、C5-C14杂芳基。
本发明所用术语“羟烷基”是指-烷基-OH,其中烷基如上所定义。本发明所用“羟烷基”的实例包括但不限于羟甲基、羟乙基、羟丙基、羟异丙基等。“羟烷基”还包括取代羟烷基,其取代基可为D、卤素、氧代、氨基、羟基、氰基、硝基、羧基、酰胺基、磺酰胺基、螺烷基、C1-C8烷基、C1-C8羟烷基、C1-C8烷氧基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8羟烷基、卤代C1-C8烷氧基、卤代C1-C8烷氨基、C3-C12环烷基、C3-C12杂环基、C6-C12芳基、C5-C14杂芳基。
本发明所用术语“烷氨基”是指烷基-NH-,其中烷基如上所定义。本发明所用“烷氨基”的实例包括但不限于甲氨基、乙氨基、丙氨基、异丙氨基等。“烷氨基”还包括取代烷氨基,其取代基可为D、卤素、氧代、氨基、羟基、氰基、硝基、羧基、酰胺基、磺酰胺基、螺烷基、C1-C8烷基、C1-C8羟烷基、C1-C8烷氧基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8羟烷基、卤代C1-C8烷氧基、卤代C1-C8烷氨基、C3-C12环烷基、C3-C12杂环基、C6-C12芳基、C5-C14杂芳基,其取代基可以取代在烷基上也可以取代在N上。
本发明所用术语“胺烷基”是指NH2-烷基-,其中烷基如上所定义。本发明所用“氨基烷基”的实例包括但不限于氨基甲基、氨基乙基、氨基丙基、氨基异丙基等。“氨基烷基”还包括取代氨基烷基,其取代基可为D、卤素、氧代、氨基、羟基、氰基、硝基、羧基、酰胺基、磺酰胺基、螺烷基、C1-C8烷基、C1-C8羟烷基、C1-C8烷氧基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8羟烷基、卤代C1-C8烷氧基、卤代C1-C8烷氨基、C3-C12环烷基、C3-C12杂环基、C6-C12芳基、C5-C14杂芳基,其取代基可以取代在烷基上也可以取代在N上。
本发明所用术语“环烷氧基”是指其中一个或多个碳原子被一个或多个氧原子取代的环烷基,其中环烷基如上所定义。本发明所用“烷氨基”的实例包括但不限于氧杂环丁烷、四氢呋喃、四氢吡喃、二恶烷等。
本发明所用术语“芳环”“芳基”是指具有6到12个碳原子的全碳单环或稠合多环的芳香性环基(稠和多环时其中一个稠合环可以部分饱和),包括但不限于苯环、萘环、蒽环、茚环、二氢茚基(茚满基)、二氢萘环、四氢萘环等。芳基可以是无取代或取代的,可以是单取代(比如邻位、间位、对位取代),也可以是双取代或者三取代等,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、酰基、酰胺基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“杂芳环”“杂芳基”指具有5到14个环原子的单环或稠合多环的芳香性环基(稠和多环时其中一个稠合环可以部分饱和),相当于上述“芳基”中一个或多个碳被杂原子例如N、O、S等置换。杂芳环可以是单环,也可以是双环,即通过两个环稠合而成。杂芳基包括但不限于吡啶基、嘧啶基、吡嗪基、哒嗪基、三嗪基、异恶唑基、异噻唑基、吡唑基、噻唑基、噻吩基、呋喃基、三唑基、恶唑基、咪唑基、吲唑基、吲嗪基、吲哚基、二氢吲哚基、异吲哚啉基、喹啉基、异喹啉基、喹喔啉基、喹唑啉基、二氢喹啉基、四氢喹啉基、二氢异喹啉基、二氢异喹啉基、四氢异喹啉基、噌啉基、蝶啶基、嘌呤基、苯并咪唑基、苯并呋喃基、苯并噻吩基、苯并噻唑基、苯并三唑基、苯并三嗪基、苯并噁二唑基、苯并噁唑基、苯并异噁唑基、咪唑并吡啶基、咪唑并噻唑基、吡咯并吡啶基、噻吩并吡咯基、噻吩并噻吩基、噻吩并吡啶基、噻吩并嘧啶基、吡唑并嘧啶基、吡咯并吡咯基、吡咯并嘧啶基、吡咯并哒嗪基、吡咯并吡嗪基、咪唑并嘧啶基、咪唑并吡嗪基、咪唑并哒嗪基、吡唑并吡啶基、吡唑并哒嗪基、吡唑并吡嗪基、嘧啶并吡啶基、嘧啶并吡嗪基、嘧啶并哒嗪基、嘧啶并嘧啶基、吡啶并吡啶基、吡啶并吡嗪基、吡啶并哒嗪基、哒嗪并哒嗪基、哒嗪并吡嗪基、吡嗪并吡嗪基等。杂芳基可以是无取代或单取代或多取代的,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、卤素、氰基、硝基、氨基、氨基烷基、羟基、羧基、羧酸酯基、酰基、酰胺基、烷基酰胺基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C1-C8烷基、C1-C8羟烷基、C1-C8烷氧基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8羟烷基、卤代C1-C8烷氧基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、C3-C12杂环基、C6-C12芳基、C5-C14杂芳基。
本发明所用术语“杂环基”是指具有3至12个环原子的单环或多环(两个单环之间用化学键连接或桥环或螺环或稠合)的非芳香性环基,具有一个及以上选自N、O、S的杂原子,且可有一个或多个化学键为双键或三键。杂环基包括但不限于吡喃基、哌啶基、哌嗪基、吗啉基、二氧六环基、氧杂环丙基、氧杂环丁基、氧杂环己基、氧杂环庚基、氧杂环辛基、氮杂环丙基、氮杂环丁基、氮杂环戊基、氮杂环庚基、氮杂环辛基、硫杂环丁烷基、硫杂环丙烷基、氮杂环辛烷基、氧氮杂基、二氮杂/>基、硫氮杂/>基、二氢呋喃基、二氢噻吩基、二氢吡喃基、四氢呋喃基、四氢噻吩基、四氢吡喃基、四氢噻喃基、四氢噻唑基、四氢咪唑基、六氢哒嗪基、六氢嘧啶基、1-氮杂螺[2.2]戊烷基、1-氮杂螺[2.3]己烷基、4-氮杂螺[2.3]己烷基、5-氮杂螺[2.3]己烷基、2-氮杂螺[3.3]庚烷基、2,6-二氮杂螺[3.3]庚烷基、2-氧杂-6-氮杂螺[3.3]庚烷、1-氮杂螺[2.5]辛烷基、2-氮杂螺[3.4]辛烷基、6-氮杂螺[3.4]辛烷基、2,6-二氮杂螺[3.4]辛烷基、2-氮杂螺[3.5]壬烷基、6-氮杂螺[3.5]壬烷基、7-氮杂螺[3.5]壬烷基、2,7-二氮杂螺[3.5]壬烷基、2-氧杂-7-氮杂螺[3.5]壬烷基、1-氮杂螺[4.4]壬烷基、2-氮杂螺[4.4]壬烷基、8-氮杂螺[4.5]癸烷基、2,8-二氮杂螺[4.5]癸烷基、1-氧杂螺[2.2]戊烷基、1-氧杂螺[2.3]己烷基、4-氧杂螺[2.3]己烷基、5-氧杂螺[2.3]己烷基、2-氧杂螺[3.3]庚烷基、1-氧杂螺[2.5]辛烷基、2-氧杂螺[3.4]辛烷基、6-氧杂螺[3.4]辛烷基、2-氧杂螺[3.5]壬烷基、6-氧杂螺[3.5]壬烷基、7-氧杂螺[3.5]壬烷基、1-氧杂螺[4.4]壬烷基、2-氧杂螺[4.4]壬烷基、8-氧杂螺[4.5]癸烷基、十氢喹啉基、十氢异喹啉基、2-氮杂双环[1.1.1]戊烷基、2-氧杂双环[1.1.1]戊烷基、氮杂双环[2.1.1]己烷基、氧杂双环[2.1.1]己烷基、氮杂双环[3.1.1]庚烷基、氧杂双环[3.1.1]庚烷基、氮杂双环[2.2.1]庚烷基、氮杂双环[4.1.1]辛烷基、氮杂双环[3.2.1]辛烷基、氮杂双环[3.2.1]辛烷基等。杂环基可被一个或多个取代基取代,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“螺环”、“螺环基”是指一种多环结构,在这种多环结构中至少有2个环存在共用一个原子(一般为C原子)的情况,在这种多环结构中可以有一个或多个化学键是双键或者三键,且可以有一个或多个杂原子存在。该螺环基可以是无取代或单取代或多取代的,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“桥环基”是指一种多环结构,在这种多环结构中至少有2个环存在共用2个或2个以上原子的情况,在这种多环结构中可以有一个或多个化学键是双键或者三键,且可以有一个或多个杂原子存在。该桥环基可以是无取代或单取代或多取代的,多取代时取代基可以相同也可以不同;所述取代基独立为D(氘)、氧代、卤素、氰基、硝基、羟基、氨基、氨基烷基、烯基、炔基、羧基、羧酸酯基、酰基、酰胺基、甲砜基、烷基酰胺基、C1-C8烷基、C1-C8烷氧基、C1-C8羟烷基、C1-C8烷氨基、卤代C1-C8烷基、卤代C1-C8烷氧基、卤代C1-C8羟烷基、卤代C1-C8烷氨基、C3-C12环烷基、卤代C3-C12环烷基、环烯基、环炔基、烷氧羰基、烷硫基、烷基磺酰基、羟烷基酰胺基、磺酰胺基、螺烷基、C6-C12芳基、C5-C14杂芳基、C3-C12杂环基。
本发明所用术语“卤代烷基”是指其中一个或多个氢被一或多个卤素原子(优选为氟、氯、溴、碘)取代的直链或支链烷基,其中烷基如上所定义。本发明所用“卤代烷基”的实例包括但不限于氟甲基、二氟甲基、三氟甲基、氯甲基、二氯甲基、三氯甲基、2-氟乙基、2,2,2-三氟乙基、2-氯乙基、四氟乙基、五氟乙基、1,1,1-三氟丙-2-基等。
本发明所用术语“卤代环烷基”是指其中一个或多个氢被一或多个卤素原子(优选为氟、氯、溴、碘)取代的环烷基,其中环烷基如上所定义。
本发明采用本领域技术人员所熟知的方法可以制备本发明所述化合物的盐。
“药学上可接受的盐”是指本发明化合物与酸或碱所形成的适合用作药物的盐。药学上可接受的盐包括无机盐和有机盐。一类优选的盐是本发明化合物与酸形成的盐。适合形成盐的酸包括但并不限于:盐酸、氢溴酸、氢氟酸、氢碘酸、硫酸、硝酸、磷酸、碳酸等无机酸,甲酸、乙酸、三氟乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、苦味酸、甲磺酸、对甲苯磺酸、乙磺酸、苯磺酸、樟脑磺酸、枸杞酸、异烟酸、水杨酸、抗坏血酸、龙胆酸、葡萄糖酸、丙酮酸、萘磺酸、硬脂酸、苯乙酸、对氨基苯磺酸、羟乙磺酸、双羟萘酸,丹宁酸等有机酸;以及天冬氨酸、谷氨酸等酸性氨基酸。一类优选的盐是本发明化合物与碱形成的盐。适合形成盐的碱包括但并不限于:氢氧化钠、氢氧化钾、碳酸钠、碳酸氢钠、磷酸钠等无机碱,氨水、三乙胺、二乙胺、哌嗪、胍、二乙醇胺等有机碱。
本发明的第二个目的是提供一种药物组合物,包括上述任意一项技术方案所述的化合物中的一种或多种。本发明所述的药物组合物可以是上述任意一项技术方案所述的化合物中的一种或多种与其他化合物组成,或者上述任意一项技术方案所述的化合物中的一种或多种组成。
本发明提供了一种药物制剂,包含至少一种活性组分,所述活性组分是如上述任意一项技术方案所述的化合物中的一种或多种。所述药物制剂包含至少一种活性组分以及一种或多种药学上可接受的载体或赋形剂,所述的活性组分可以是本发明的BTK抑制剂化合物、所述化合物的光学异构体、所述化合物或其光学异构体在药学上可接受的盐、所述化合物或其光学异构体的溶剂合物中的任意一种或任意多种。
所述载体包括药学领域的常规稀释剂,赋形剂,填充剂,粘合剂,湿润剂,崩解剂,吸收促进剂,表面活性剂,吸附载体,润滑剂等,必要时还可以加入香味剂,甜味剂等。
本发明药物可以制成片剂,粉剂,粒剂,胶囊,口服液及注射用药等多种形式,上述各剂型的药物均可以按照药学领域的常规方法制备。
另一方面,本发明提供的是使用本文公开的通式I~通式III所述的化合物及其光学异构体或其药学上可接受的盐或溶剂合物来抑制布鲁顿酪氨酸激酶(Btk)活性或者治疗从布鲁顿酪氨酸激酶(Btk)活性的抑制中获益的疾病、障碍或病症。
在进一步优选的方案中,本发明提供的是通过给予有需要的治疗者一种含有治疗有效量的至少一种化合物的组合物、从而抑制所述受治疗者的布鲁顿酪氨酸激酶活性的方法,其中所述化合物的结构式为通式I~通式III。在一些实施方式中,有需要的受治疗者罹患自身免疫性疾病,例如炎性肠病、关节炎、狼疮、类风湿性关节炎、银屑病性关节炎、骨关节炎、斯蒂尔病(Still’s disease)、青少年关节炎、糖尿病、重症肌无力症、桥本甲状腺炎(Hashimoto’s thyroiditis)、奥德甲状腺炎(Ord’s thyroiditis)、格雷夫斯氏病(Graves’disease)、类风湿性关节炎综合征(syndrome)、多发性硬化症、传染性神经元炎(Guillain-Barrésyndrome)、急性播散性脑脊髓炎、阿狄森病(Addison’sdisease)、视性眼阵挛-肌阵挛综合征、强制性脊椎炎、抗磷脂抗体综合征、再生障碍性贫血、自身免疫性肝炎、乳糜泻(coeliac disease)、古德帕斯彻综合征(Goodpasture’ssyndrome)、免疫性血小板减少性紫癜(ITP)、视神经炎、硬皮病、原发性胆汁性肝硬化、莱特尔综合征(Reiter’s syndrome)、高安动脉炎(Takayasu’s arteritis)、颞动脉炎、温型自身免疫性溶血性贫血、韦格纳肉芽肿病(Wegener’s granulomatosis)、银屑病、全身脱毛、贝赫切特病(/>disease)、慢性疲劳、家族性自主神经功能异常、子宫内膜异位、间质性膀胱炎、神经肌强直、硬皮病或外阴痛和慢性移植物抗宿主病(cGvHD)。
在进一步的实施方式中,有需要的受治疗者罹患癌症。在一个实施方式中,所述癌症是B细胞或浆细胞增生性疾病,例如弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、慢性淋巴细胞淋巴瘤、慢性淋巴细胞白血病、B细胞前淋巴细胞性白血病、淋巴浆细胞淋巴瘤/瓦尔登斯特伦巨球蛋白血症(macroglobulinemia)、脾边缘区淋巴瘤、浆细胞性骨髓瘤、浆细胞瘤、结外边缘区B细胞淋巴瘤、淋巴结边缘区B细胞淋巴瘤、外套细胞淋巴瘤、纵膈(胸腺)大B细胞淋巴瘤、血管内大B细胞淋巴瘤、原发性渗出性淋巴瘤、伯基特淋巴瘤(Burkittlymphoma)/白血病、多发性骨髓瘤或淋巴瘤样肉芽肿病。
本发明还提供本发明所述的化合物或其可药用盐在制备BTK抑制剂中的应用,特别是在制备治疗细胞增生疾病中的应用。所述的细胞增生疾病包括癌症。换言之,本发明还提供通式I~通式III所述的化合物、及其光学异构体或其药学上可接受的盐或溶剂合物单独或和其他药物联合使用在治疗增生类疾病(如癌症)中的应用。能和本发明所提供的化合物或其可药用盐联合使用的抗肿瘤药包括但并非限定至少一种以下种类:有丝分裂抑制剂(如长春碱、长春地辛和长春瑞宾);微管蛋白分解抑制剂(如泰素));烷基化试剂(如顺铂、卡铂和环磷酰胺);抗代谢物(如5-氟尿嘧啶、替加氟、甲氨蝶呤、阿糖胞苷和羟基脲);可插入抗生素(如阿雷素、丝裂霉素和争光霉素));酶(如天门冬氨酶);拓朴异构酶抑制剂(如依托伯苷和喜树碱);生物反应调节剂(如干扰素);免疫检查点抑制剂(如PD-1抑制剂、PD-L1抑制剂、CTLA-4抑制剂);CD20单抗;BCL2抑制剂。
本发明发明人通过实验证实,本发明化合物对BTK具有降解活性。
本发明发明人通过实验证实,本发明化合物对Mino、OCI-LY10等肿瘤细胞株具有抗增殖抑制作用。
本发明发明人通过实验证实,本发明化合物在肝微粒中代谢稳定。
本发明发明人通过实验证实,本发明化合物可口服。
本发明发明人通过实验证实,本发明化合物在OCI-LY10体内药效模型中具有较好的抑制肿瘤生长的效果。
具体实施方式
中间体1:4-(4-((6-氨甲酰-3-(甲硫基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-羧酸叔丁酯
将5-氯-3-(甲硫基)-1,2,4-三嗪-6-羧酸乙酯(760 mg,3.40 mmol)溶于10 mL乙腈中,向体系依次加入4-(4-氨基-2-氟苯基)哌啶-1-羧酸叔丁酯(1.0g,3.40mmol),N,N-二异丙基乙胺(1.2mL,6.80mmol),室温反应0.5h,再向体系加入氨的甲醇溶液(25mL,1mmol/mL),室温反应0.5h。反应结束后,加水过滤,减压浓缩得到中间体1固体1.3g,收率:86%。ESI-MS(M+H)+=463。
中间体2:4-(4-((6-氨基甲酰基-3-(甲硫基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-羧酸叔丁酯
参考中间体1的合成路线和方法,把4-(4-氨基-2-氟苯基)哌啶-1-羧酸叔丁酯替换为4-(4-氨基苯基)哌啶-1-羧酸叔丁酯,合成得到中间体2。ESI-MS(M+H)+=445。
中间体3:4-(4-((5-氨基甲酰基-2-(甲硫基)嘧啶-4-基)氨基)-2-氟苯基)哌啶-1-羧酸叔丁酯
参考中间体1的合成路线和方法,把5-氯-3-(甲硫基)-1,2,4-三嗪-6-羧酸乙酯替换为4-氯-2-甲硫基嘧啶-5-羧酸乙酯,合成得到中间体3。ESI-MS(M+H)+=462。
参考中间体1的合成路线和方法,合成得到如下中间体结构:
中间体16:5-((3-氟-4-(4-甲酰基哌啶-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺
合成步骤1:1-(2-氟-4-硝基苯基)哌啶-4-甲醛(中间体16-1)
将4-甲酰哌啶-1-羧酸叔丁酯(7.3g,34.27mmol)溶于20mL DCM中,向体系中加入三氟乙酸(30mL),室温搅拌一小时。反应结束,减压浓缩,得黄色液体哌啶-4-甲醛。将上述产物溶于50mL DMF中,向体系中依次加入碳酸铯(3.0g,9.21mmol),2,4-二氟-1-硝基苯(5.5g,31.44mmol),90℃反应2h。反应结束,加水淬灭,EA萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,得黄色液体1-(2-氟-4-硝基苯基)哌啶-4-甲醛7.5g,收率94%。ESI-MS(M+H)+=253。
合成步骤2:4-(1,3-二氧戊环-2-基)-1-(2-氟-4-硝基苯基)哌啶(中间体16-2)
将中间体16-1(7.5g,29.64mmol)溶于50mL甲苯中,向体系中依次加入对甲苯磺酸(563mg,2.96mmol),乙二醇(18mL,296.40mmol),于120℃反应12h。反应结束。加水淬灭,减压浓缩,加水有固体析出,过滤,得棕黑色固体4-(1,3-二氧戊环-2-基)-1-(2-氟-4-硝基苯基)哌啶7g,收率80%。ESI-MS(M+H)+=297。
合成步骤3:4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯胺(中间体16-3)
将中间体16-2(7g,23.64mmol)溶于70mL四氢呋喃中,向体系中依次加入氯化铵(13g,236.48mmol),水(10mL),铁粉(12g,236.48mmol),于70℃反应12h。反应结束,EA萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(乙酸乙酯/石油醚)得黄色固体4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯胺3.4g,收率54%。ESI-MS(M+H)+=267。
合成步骤4:5-((4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯基)氨基)-3-(甲硫基)-1,2,4-三嗪-6-甲酰胺(中间体16-4)
将中间体16-3(1.5g,5.63mmol)溶于15mL乙腈中,向体系中依次加入DIPEA(1.81g,14.07mmol)、5-氯-3-(甲硫基)-1,2,4-三嗪-6-羧酸乙酯(1.3g,5.63mmol),室温反应30min后,向其加入氨的甲醇溶液(7mol/L,15mL),10min内体系变浑浊,于室温下继续反应2h。反应结束,减压浓缩,石油醚打浆,过滤,得黄色固体5-((4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯基)氨基)-3-(甲硫基)-1,2,4-三嗪-6-甲酰胺2.1g,收率83%。ESI-MS(M+H)+=435。
合成步骤5:5-((4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(中间体16-5)
将中间体16-4(1g,2.00mmol)溶于10mL NMP中,向体系中加入mCPBA(85%,1.8g,10.00mmol),于室温搅拌2h。待反应结束,向体系中依次加入DIPEA(1.1mL,6.00mmol),哌啶(653mg,3.00mmol),于80℃反应2h。反应结束,加水淬灭,EA萃取五次,合并有机相,用饱和氯化钠水溶液洗涤有机相2次,无水硫酸钠干燥,减压浓缩,所得粗产物经柱层析(二氯甲烷/甲醇洗脱)得黄色固体5-((4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺690mg,收率73%。ESI-MS(M+H)+=472。
合成步骤6:5-((3-氟-4-(4-甲酰基哌啶-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(中间体16)
将中间体16-5(690mg,1.46mmol)溶于3mL四氢呋喃中,向体系中加入3N HCl(7mL),于80℃反应3h。反应结束,向体系中加入饱和碳酸氢钠水溶液调至碱性,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(甲醇/二氯甲烷体系)得中间体16黄色固体380mg,收率57%。ESI-MS(M+H)+=428。
参考中间体16的合成路线和方法,合成得到如下中间体结构:
中间体23:4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-羧酸叔丁酯
合成步骤1:3-((4-溴苯基)氨基)丙酸(中间体23-1)
将4-溴苯胺(5.00g,29.06mmol)溶于40mL甲苯中,向体系中加入丙烯酸(2.50g,34.87mmol),于100℃反应12h。反应结束,加水淬灭,减压浓缩,经柱层析(PE/EA洗脱)可得黄色固体3-((4-溴苯基)氨基)丙酸2.8g,收率39%。ESI-MS:m/z=244[M+H]+。
合成步骤2:1-(4-溴苯基)二氢嘧啶-2,4(1H,3H)-二酮(中间体23-2)
将中间体23-1(2.80g,11.52mmol)溶于30mL醋酸中,向体系加入尿素(1.40g,23.04mmol),于120℃反应12h。反应结束,加水有固体析出,过滤得黄色固体,加DCM溶解,用无水硫酸钠干燥,减压浓缩,经柱层析(DCM/MeOH洗脱)可得固体1-(4-溴苯基)二氢嘧啶-2,4(1H,3H)-二酮1.1g,收率35%。ESI-MS:m/z=269[M+H]+。
合成步骤3:4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-羧酸叔丁酯(中间体23)
将中间体23-2(150mg,0.55mmol)溶于3mL 1,4-二氧六环溶液中,向体系中依次加入哌嗪-1-羧酸叔丁酯(156mg,0.83mmol),叔丁醇钠(162mg,1.65mmol),碳酸铯(536mg,1.65mmol),醋酸钯(12mg,0.05mmol),三(二亚苄基丙酮)二钯(45mg,0.05mmol)、X-phos(52mg,0.11mmol),于90℃反应12h。反应结束,加水淬灭,用EA萃取3次,合并有机相,无水硫酸钠干燥,浓缩经柱层析(PE/EA洗脱)可得4-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)苯基)哌嗪-1-羧酸叔丁酯80mg,收率38%。ESI-MS:m/z=375[M+H]+。
中间体24:1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-羧酸
将2-(2,6-二氧代哌啶-3-基)-5-氟异吲哚啉-1,3-二酮(500mg,1.81mmol)溶于8mL DMSO中,向体系中依次加入吡咯烷-3-羧酸(312mg,2.72mmol)、DIPEA(701mg,5.43mmol),于90℃反应12h。反应结束,加水,DCM萃取三次,合并有机相,饱和氯化铵水溶液洗涤有机相,无水硫酸钠干燥,减压浓缩,经柱层析得中间体24,550mg,收率81%。ESI-MS(M+H)+=372。
中间体25:4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-羧酸叔丁酯
参考中间体24合成路线和方法,把吡咯烷-3-羧酸替换为哌嗪-1-羧酸叔丁酯,合成得到中间体25。ESI-MS(M+H)+=443。
中间体26:4-(2-(2,6-二氧代哌啶-3-基)-6-氟-1,3-二氧代异吲哚啉-5-基)哌嗪-1-羧酸叔丁酯
参考中间体25的合成路线和方法,把2-(2,6-二氧代哌啶-3-基)-5-氟异吲哚啉-1,3-二酮替换为2-(2,6-二氧代哌啶-3-基)-5,6-二氟异吲哚啉-1,3-二酮,合成得到中间体26。ESI-MS(M+H)+=461。
中间体27:1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-氟苯基)哌啶-4-甲醛
合成步骤1:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-硝基苯胺(中间体27-1)
将5-氟-2-硝基苯胺(1g,6.41mmol)溶于10mL DMF中,向体系中依次加入4-(1,3-二氧戊环-2-基)哌啶(1.2g,7.69mmol),碳酸铯(6.2g,19.23mmol),80℃反应3h。反应结束,加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-硝基苯胺1.5g,收率79%,ESI-MS(M+H)+=294。
合成步骤2:4-(1,3-二氧戊环-2-基)-1-(3-氟-4-硝基苯基)哌啶(中间体27-2)
将中间体27-1(1.5g,5.11mmol)溶于15mL浓盐酸,在0℃向体系中加入HF(70%,30mL),室温反应至反应完全溶解,在-78℃下向体系中加入NaNO2(423mg,6.13mmol),0℃反应30min后升温至60℃反应15-30min。反应结束,加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得4-(1,3-二氧戊环-2-基)-1-(3-氟-4-硝基苯基)哌啶1g,收率66%。ESI-MS(M+H)+=297。
合成步骤3:4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯胺(中间体27-3)
将中间体27-2(1g,3.37mmol)溶于10mL四氢呋喃中,向体系中依次加入氯化铵(2g,33.78mmol),水(10mL),铁粉(1.9g,33.78mmol),70℃反应12h。反应结束,用硅藻土过滤除去铁粉,滤液用DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(EA/PE洗脱)纯化得4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯胺750mg,收率83%。ESI-MS(M+H)+=267。
合成步骤4:3-(4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯基)氨基)丙酸(中间体27-4)
将中间体27-3(750mg,2.81mmol)溶于10mL甲苯中,向体系中加入丙烯酸(243mg,3.38mmol),100℃反应12h,反应结束。DCM萃取五次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得黄色液体3-(4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯基)氨基)丙酸860mg,收率90%。ESI-MS(M+H)+=339。
合成步骤5:1-(4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯基)二氢嘧啶-2,4(1H,3H)-二酮(中间体27-5)
将中间体27-4(860mg,2.54mmol)溶于10mL醋酸中,向体系加入尿素(315mg,5.08mmol),120℃反应12h。反应结束,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(DCM/MeOH洗脱)得棕黄色固体1-(4-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-氟苯基)二氢嘧啶-2,4(1H,3H)-二酮540mg,收率58%。ESI-MS(M+H)+=364。
合成步骤6:1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-氟苯基)哌啶-4-甲醛(中间体27)
将中间体27-5(540mg,1.68mmol)溶于6mL TFA中,80℃反应1h后向体系中加入浓盐酸0.5mL,80℃反应3h。反应结束,加饱和碳酸钠水溶液调至偏碱性,MeOH/DCM萃取五次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得到中间体27固体490mg,收率91%。ESI-MS(M+H)+=320。
参考中间体27的合成路线和方法,合成得到如下中间体结构:
中间体33:N-(2,6-二氧代哌啶-3-基)-5-(4-甲酰基哌啶-1-基)吡啶甲酰胺
合成步骤1:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶甲酸甲酯(中间体33-1)
将5-氟吡啶-2-甲酸甲酯(2.2g,14.18mmol)溶于20mL DMF中,向体系中加入4-(1,3-二氧戊环-2-基)哌啶(2.7g,17.02mmol),碳酸钾(5.8g,42.54mmol),90℃反应2h。反应结束,加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得黄色固体5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-甲酸甲酯3.2g,收率78%。ESI-MS(M+H)+=293。
合成步骤2:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶甲酸(中间体33-2)
将中间体33-1(1.5g,5.13mmol)溶于20mL四氢呋喃中,向体系中加入氢氧化锂(615mg,25.67mmol)、水(7.5mL),室温反应2h,反应结束,浓缩至无溶剂,DCM打浆,过滤,浓缩滤液得到白色固体5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-甲酸1.3g,收率93%。ESI-MS(M+H)+=279。
合成步骤3:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-N-(2,6-二氧代哌啶-3-基)吡啶甲酰胺(中间体33-3)
将中间体33-2(500mg,1.08mmol)溶于10mL DMF中,向体系中依次加入3-氨基哌啶-2,6-二酮(255mg,1.97mmol)、HATU(752mg,1.97mmol)、三乙胺(0.75mL,5.39mmol),室温反应1h。反应结束,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(DCM/MeOH洗脱)得灰色固体5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-N-(2,6-二氧代哌啶-3-基)吡啶甲酰胺350g,收率51%。ESI-MS(M+H)+=389。
合成步骤4:N-(2,6-二氧代哌啶-3-基)-5-(4-甲酰基哌啶-1-基)吡啶甲酰胺(中间体33)
将中间体33-3(100mg,0.26mmol)溶于2mL TFA中,80℃反应1h后,向体系中加入1mL浓盐酸,80℃反应3h。反应结束,加饱和碳酸钠水溶液调节体系至偏碱性,DCM萃取五次,合并有机相,无水硫酸钠干燥,减压浓缩,得中间体33黄色固体75mg,收率84%。ESI-MS(M+H)+=345。
参考中间体33的合成路线和方法,合成得到如下中间体结构:
中间体36:1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-甲醛
合成步骤1:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-硝基吡啶(中间体36-1)
将5-氟-2-硝基吡啶(1.5g,10.56mmol)溶于20mL DMF中,向体系中加入4-(1,3-二氧戊环-2-基)哌啶(1.8g,12.67mmol),碳酸铯(10g,31.68mmol),80℃反应2h。反应结束,加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得固体5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-2-硝基吡啶2g,收率69%。ESI-MS(M+H)+=280。
合成步骤2:5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-胺(中间体36-2)
将中间体36-1(2g,7.31mmol)溶于25mL四氢呋喃中,向体系中依次加入氯化铵(3.9g,73.12mmol),水(5mL),铁粉(4.1g,73.12mmol),于70℃反应12h。反应结束,趁热过滤掉大量的铁粉,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-胺1.6g,收率89%。ESI-MS(M+H)+=250。
合成步骤3:3-((5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-基)氨基)哌啶-2,6-二酮(中间体36-3)
将中间体36-2(1.6g,6.49mmol)溶于20mL DMF中,向体系中依次加入3-溴哌啶-2,6-二酮(1.9g,9.74mmol),Pd(dppf)Cl2(472mg,0.65mmol),Na2CO3(2.1g,19.47mmol),于100℃反应3h。反应结束,加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得3-((5-(4-(1,3-二氧戊环-2-基)哌啶-1-基)吡啶-2-基)氨基)哌啶-2,6-二酮1.9g,收率82%。ESI-MS(M+H)+=361。
合成步骤4:1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-甲醛(中间体36)
将中间体36-3(1.9g,5.35mmol)溶于10mL TFA中,80℃反应1h。然后向体系中加入浓盐酸2mL,80℃反应3h。反应结束,加饱和碳酸钠水溶液调至偏碱性,DCM萃取五次,合并有机相,无水硫酸钠干燥,减压浓缩得到中间体36固体1.4g,收率83%。ESI-MS(M+H)+=317。
参考中间体36的合成路线和方法,合成得到如下中间体结构:
中间体39:1-(5-(6-氧-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-甲醛
合成步骤1:(6-氯-5-(三氟甲基)吡啶-3-基)硼酸(中间体39-1)
将5-溴-2-氯-3-(三氟甲基)吡啶(5g,19.20mmol)溶于50mL 1,4-二氧六环中,向体系中依次加入联硼酸频那醇酯(4.8g,19.20mmol)、醋酸钾(4.7g,48.12mmol)、Pd(dppf)Cl2(1.39g,1.92mmol),氩气氛围下于100℃反应6h,反应结束。DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,得(6-氯-5-(三氟甲基)吡啶-3-基)硼酸4g,收率92%,ESI-MS(M+H)+=226。
合成步骤2:3-氯-6-(6-氯-5-(三氟甲基)吡啶-3-基)哒嗪(中间体39-2)
将中间体39-1(2g,8.88mmol)溶于20mL乙腈中,向体系中依次加入3,6-二氯哒嗪(1.7g,11.54mmol)、碳酸钾(3.4g,26.64mmol)、水(2mL)、PdCl2(pph3)2(616mg,0.88mmol),于80℃反应4h。反应结束后,减压浓缩,得3-氯-6-(6-氯-5-(三氟甲基)吡啶-3-基)哒嗪700mg,收率26%,ESI-MS(M+H)+=294。
合成步骤3:6-(6-氯-5-(三氟甲基)吡啶-3-基)哒嗪-3-醇(中间体39-3)
将中间体39-2(700mg,2.38mmol)溶于9mL 1,4-二氧六环中,向体系中加入3MHCl,于110℃反应4h,反应结束。DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,得6-(6-氯-5-(三氟甲基)吡啶-3-基)哒嗪-3-醇440mg,收率67%,ESI-MS(M+H)+=276。
合成步骤4:6-(6-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-5-(三氟甲基)吡啶-3-基)哒嗪-3(2H)-酮(中间体39-4)
将中间体39-3(440mg,1.60mmol)溶于5mL DMF中,向体系中加入4-(1,3-二氧戊环-2-基)哌啶(376mg,2.40mmol)、碳酸铯(1.5g,4.80mmol),于120℃反应12h,反应结束。加水淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,得6-(6-(4-(1,3-二氧戊环-2-基)哌啶-1-基)-5-(三氟甲基)吡啶-3-基)哒嗪-3(2H)-酮344mg,收率54%,ESI-MS(M+H)+=397。
合成步骤5:1-(5-(6-氧-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-甲醛(中间体39)
将中间体39-4(140mg,0.35mmol)溶于2mL TFA中,于80℃反应1h后,向体系中加入浓盐酸0.1mL,继续80℃反应1h,反应结束。加饱和碳酸钠水溶液调至中性或偏碱性,DCM萃取五次,合并有机相,无水硫酸钠干燥,减压浓缩,得1-(5-(6-氧代-1,6-二氢哒嗪-3-基)-3-(三氟甲基)吡啶-2-基)哌啶-4-甲醛100mg,收率81%。ESI-MS(M+H)+=353。
参考中间体39的合成路线和方法,合成得到如下中间体结构:
实施例41:4-(5-(2,6-二氧代哌啶-3-基)吡啶-2-基)哌嗪-1-羧酸叔丁酯
合成步骤1:(6-(4-(叔丁氧羰基)哌嗪-1-基)吡啶-3-基)硼酸(中间体40-1)
将4-(5-溴吡啶-2-基)哌嗪-1-甲酸叔丁酯(1.4g,4.09mmol)溶于15mL 1,4-二氧六环中,向体系中依次加入联硼酸频那醇酯(1.0g,4.09mmol),醋酸钾(1.2g,12.27mmol)、Pd(dppf)Cl2(232mg,0.32mmol),氩气氛围下于100℃反应6h,反应结束。过滤后滤液加水,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得(6-(4-(叔丁氧羰基)哌嗪-1-基)吡啶-3-基)硼酸1.0g,收率79%。ESI-MS(M+H)+=308。
合成步骤2:4-(2',6'-双(苄氧基)-[3,3'-联吡啶]-6-基)哌嗪-1-羧酸叔丁酯(中间体40-2)
将中间体40-1(950mg,3.09mmol)溶于15mL 1,4-二氧六环中,向体系中依次加入2,6-双(苄氧基)-3-溴吡啶(2.29g,6.19mmol),醋酸铯(3.0g,9.28mmol),Pd(dppf)Cl2(224mg,0.30mmol),氩气氛围下于100℃反应12h,反应结束。过滤后滤液加水,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析得4-(2',6'-双(苄氧基)-[3,3'-联吡啶]-6-基)哌嗪-1-羧酸叔丁酯1.2g,收率70%。ESI-MS(M+H)+=553。
合成步骤3:4-(5-(2,6-二氧代哌啶-3-基)吡啶-2-基)哌嗪-1-羧酸叔丁酯(中间体40)
将中间体40-2(1.0g,1.81mmol)溶于20mL甲醇中,向体系中依次加入Pd/C(400mg),氢气环境下室温反应24h。反应结束后,过滤,减压浓缩,经柱层析得4-(5-(2,6-二氧代哌啶-3-基)吡啶-2-基)哌嗪-1-羧酸叔丁酯320mg,收率47%,ESI-MS(M+H)+=375。
参考中间体41的合成路线和方法,合成得到如下中间体结构:
实施例1:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(002)
合成步骤1:4-(4-((6-氨基甲酰基-3-羟基-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-羧酸叔丁酯(002-1)
将中间体1(1.3g,2.81mmol)溶于20mL NMP中,向体系中加入mCPBA(85%,5.0g,28.93mmol),于室温搅拌2h,然后向体系中依次加入DIPEA(4.5g,34.82mmol),水(10mL),继续室温反应2h。反应结束,加水25mL,过滤,滤饼经柱层析(二氯甲烷/甲醇洗脱)得橙黄色固体4-(4-((6-氨基甲酰基-3-羟基-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-羧酸叔丁酯350mg,收率30%。ESI-MS(M+H)+=433。
合成步骤2:3-((4-(4-((6-氨基甲酰基-3-羟基-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-基)甲基)吡咯烷-1-羧酸叔丁酯(002-2)
将002-1(350mg,0.81mmol)溶于5mL DCM中,向体系中加入三氟乙酸(3mL),于室温下搅拌1h。反应结束,减压浓缩,得黄色液体。将上述产物溶于10mL DCM中,依次加入DIPEA(314mg,2.43mmol)、3-甲酰基吡咯烷-1-羧酸叔丁酯(323mg,1.62mmol),室温搅拌10min,向体系加入醋酸(0.5mL),氰基硼氢化钠(101mg,1.62mmol),继续室温反应1h。反应结束,加饱和碳酸氢钠水溶液淬灭,DCM萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,经柱层析(DCM/MeOH洗脱)得黄色固体3-((4-(4-((6-氨基甲酰基-3-羟基-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌啶-1-基)甲基)吡咯烷-1-羧酸叔丁酯210mg,收率:50%。ESI-MS(M+H)+=516。
合成步骤3:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-羟基-1,2,4-三嗪-6-甲酰胺(002-3)
将002-2(210mg,0.41mmol)溶于5mL DCM中,向体系加入三氟乙酸(2mL),室温搅拌1h。反应结束,减压浓缩,得黄色液体。将上述产物溶于5mL DMSO中,向体系依次加入DIPEA(1.48g,11.44mmol),2-(2,6-二氧代哌啶-3-基)-5-氟异吲哚啉-1,3-二酮(280mg,1.02mmol),于95℃反应12h。反应结束,加水有固体析出,过滤得黄色固体,加DCM溶解,无水硫酸钠干燥,减压浓缩。经柱层析(DCM/MeOH洗脱)得黄色固体5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-羟基-1,2,4-三嗪-6-甲酰胺200mg,收率:73%。ESI-MS(M+H)+=672。
合成步骤4:3-氯-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺(002-4)
将002-3(200mg,0.29mmol)溶于10mL 1,4-二氧六环中,向体系依次加入N,N-二异丙基乙胺(1.5g,11.50mmol),三氯氧磷(2mL),于105℃反应0.2h。反应结束后,缓慢倒入20mL水中,加碳酸氢钠调节至pH值大于7,过滤,滤饼即粗产物3-氯-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-1,2,4-三嗪-6-甲酰胺200mg,收率:99%。ESI-MS(M+H)+=690。
合成步骤5:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(002)
将002-4(100mg,0.14mmol)溶于3mL DMF,向体系依次加入哌啶(18mg,0.20mmol),N,N-二异丙基乙胺(40mg,0.31mmol),于75℃反应0.5h。反应结束后,加水至体系不再有黄色固体析出止,固体经柱层析后得到化合物002固体54mg,收率:53%。ESI-MS(M+H)+=739。1H-NMR(400MHz,CCl3D)δ11.00(brs,1H),8.20(brs,1H),7.57-7.72(m,3H),7.22-7.23(m,2H),6.96-6.97(m,1H),6.68-6.71(m,1H),5.45(brs,1H),4.92-4.96(m,1H),3.70-4.01(m,4H),3.40-3.61(m,3H),3.17-3.22(m,1H),2.60-3.19(m,6H),2.41-2.48(m,2H),2.08-2.25(m,3H),1.73-1.89(m,10H),1.25-1.29(m,3H).
实施例2:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(001)
参考实施例1的合成路线和方法,把合成步骤1中的中间体1替换为中间体2,合成得到目标化合物001,ESI-MS(M+H)+=721。1H-NMR(400MHz,CCl3D)δ10.89(brs,1H),8.02(brs,1H),7.60-7.71(m,4H),7.23-7.25(m,2H),6.97-6.98(m,1H),6.68-6.71(m,1H),5.36-5.38(m,1H),4.91-4.96(m,1H),3.77-4.02(m,4H),3.38-3.62(m,3H),3.19-3.24(m,1H),2.94-3.08(m,2H),2.64-2.92(m,4H),2.41-2.51(m,3H),2.00-2.23(m,7H),1.71-1.86(m,8H).
实施例3:5-((4-(4-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(003)
参考实施例1的合成路线和方法,把合成步骤1中的中间体1替换为中间体4,合成得到目标化合物003,ESI-MS(M+H)+=740。1H-NMR(400MHz,CDCl3)δ10.88(brs,1H),8.37(s,1H),7.60 -7.71(m,3H),7.18-7.22(m,1H),6.92-6.96(m,2H),6.68-6.70(m,1H),5.53(brs,1H),4.91-4.96(m,1H),3.38-3.91(m,6H),3.09-3.23(m,5H),2.61-2.91(m,6H),2.40-2.53(m,2H),1.99-2.26(m,2H),1.68-1.89(m,7H),1.24-1.33(m,3H).
实施例4:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌啶-4-基)甲基)哌啶-4-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(007)
参考实施例1的合成路线和方法,把合成步骤2中的3-甲酰基吡咯烷-1-羧酸叔丁酯替换为4-甲酰基哌啶-1-羧酸叔丁酯,合成得到目标化合物007,ESI-MS(M+H)+=753。1H-NMR(400MHz,CDCl3)δ11.00(brs,1H),8.34(s,1H),7.60-7.72(m,3H),7.28-7.29(m,1H),7.20-7.23(m,2H),7.03-7.05(m,1H),5.51(brs,1H),4.92-4.96(m,1H),3.94-3.96(m,4H),2.77-3.01(m,9H),1.91-2.27(m,6H),1.68-1.81(m,11H),1.28-1.35(m,4H).
实施例5:5-((4-(1-((1-(1-(2,6-二氧代哌啶-3-基)-3-甲基-2-氧代-2,3-二氢-1H-苯并[d]咪唑-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(011)
参考实施例1的合成路线和方法,把合成步骤3中的2-(2,6-二氧哌啶-3-基)-5-氟异吲哚啉-1,3-二酮替换为3-(5-氟-3-甲基-2-氧代-2,3-二氢-1H-苯并[d]咪唑-1-基)哌啶-2,6-二酮,合成得到目标化合物011,ESI-MS(M+H)+=722。
实施例6:3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺(016)
合成步骤1:(R)-3-乙酰氨基哌啶-1-羧酸叔丁酯(016-1)
将(R)-3-氨基哌啶-1-羧酸叔丁酯(100mg,0.50mmol)溶于3mL DCM中,向体系中依次加入乙酸酐(76mg,0.75mmol),三乙胺(86mg,0.85mmol),于室温反应0.5h。反应结束,DCM萃取,合并有机相,饱和碳酸氢钠水溶液洗涤,饱和氯化铵水溶液洗涤,饱和氯化钠水溶液洗涤,无水硫酸钠干燥,减压浓缩,得无色液体(R)-3-乙酰氨基哌啶-1-羧酸叔丁酯110mg,收率90%。ESI-MS(M+H)+=243。
合成步骤2:3-氯-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺(016-2)
参考实施例1合成步骤1-4的合成路线和方法,把合成步骤1中的中间体1替换为中间体2,合成得到3-氯-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺,ESI-MS(M+H)+=672。
合成步骤3:3-((R)-3-乙酰氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺(016)
将016-1溶于5mL DCM中,向体系中加入三氟乙酸(1mL),室温反应1h,减压浓缩,得无色液体(R)-N-(哌啶-3-基)乙酰胺,直接用于下一步反应。将016-2(50mg,0.07mmol)溶于3mL DMF,向体系依次加入(R)-N-(哌啶-3-基)乙酰胺(50mg,0.21mmol),N,N-二异丙基乙胺(40mg,0.31mmol),于室温反应0.5h。反应结束后,加水至体系不再有黄色固体析出止,固体经柱层析后得到化合物016固体35mg,收率:60%。ESI-MS(M+H)+=778。1H-NMR(400MHz,CCl3D)δ10.95(brs,1H),8.37(brs,1H),7.73(brs,1H),7.58-7.66(m,3H),7.24-7.27(m,2H),6.96-6.97(m,1H),6.68-6.70(m,1H),5.71-5.73(m,1H),5.57(brs,1H),4.92-4.96(m,1H),3.78-4.13(m,4H),3.38-3.61(m,3H),2.63-3.23(m,6H),2.38-2.51(m,3H),2.03-2.23(m,4H),1.93(s,3H),1.77-1.85(m,8H),1.27-1.31(m,3H).
实施例7:3-((R)-3-氨基哌啶-1-基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺(029)
将016-2(145mg,0.22mmol)溶于5mL DCM,向体系依次加入(R)-哌啶-3-基氨基甲酸叔丁酯(65mg,0.32mmol),N,N-二异丙基乙胺(40mg,0.31mmol),于室温反应0.5h。反应结束后,加水淬灭,DCM萃取,饱和氯化铵水溶液洗涤,浓缩后经柱层析后得到纯化固体。将上述固体溶于3mL DCM,滴加氯化氢的1,4-二氧六环溶液(0.3mL,4.0mol/L),室温搅拌0.5h。反应结束,减压浓缩,得到化合物029黄色固体35mg,收率97%。ESI-MS(M+H)+=736。1H-NMR(400MHz,DMSO-d6)δ11.52(brs,1H),11.07(brs,1H),8.31-8.39(m,3H),7.85(s,1H),7.65-7.70(m,3H),7.32-7.33(m,2H),6.95(s,1H),6.83-6.85(m,1H),5.03-5.08(m,1H),3.78-3.82(m,1H),3.60-3.68(m,4H),3.05-3.24(m,6H),2.83-2.92(m,3H),2.54-2.63(m,2H),2.16-2.32(m,2H),1.62-2.02(m,10H),1.23-1.27(m,3H).参考实施例1-7的合成路线和方法,合成得到如下目标化合物:
实施例39:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(噻唑-2-基)-1,2,4-三嗪-6-甲酰胺(024)
将016-2(50mg,0.07mmol)、2-(三丁基锡酰基)噻唑(45mg,0.12mmol)、碳酸钠(22mg,0.21mmol)、四(三苯基膦)钯(0)(25mg)和1,4-二氧六环溶液(1mL)的混合物置于50℃下搅拌过夜反应。反应结束,加水和DCM萃取,分离有机相,无水硫酸镁干燥,过滤浓缩,经柱层析纯化得到化合物024固体21mg,收率:43%。ESI-MS(M+H)+=721。
参考实施例39的合成路线和方法,合成得到如下目标化合物:
实施例42:5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-3-(3-羟基苯氧基)-1,2,4-三嗪-6-甲酰胺(027)
将016-2(50mg,0.07mmol)溶于2mL DMSO中,向体系中依次加入间苯二酚(13mg,0.12mmol)、碳酸铯(39mg,0.12mmol),于50℃反应3h。反应结束,加水和DCM萃取,分离有机相,无水硫酸镁干燥,过滤浓缩,经柱层析纯化得化合物027固体37mg,收率:70%。ESI-MS(M+H)+=746。
实施例43:3-(2,3-二氟苯氧基)-5-((4-(1-((1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-基)甲基)哌啶-4-基)苯基)氨基)-1,2,4-三嗪-6-甲酰胺(028)
参考实施例42的合成方法和路线,把间苯二酚替换为2,3-二氟苯酚,可合成得到化合物028,ESI-MS(M+H)+=766。
实施例44:5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(075)
合成步骤1:4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌嗪-1-羧酸叔丁酯(075-1)
将中间体4(1.6g,3.45mmol)溶于25mL NMP中,向体系中加入mCPBA(85%,2.9g,17.25mmol),于室温搅拌2h。反应结束,向体系依次加入DIPEA(1.3g,10.35mmol),哌啶(439mg,5.17mmol),于80℃反应2h。反应结束,加水有固体析出,过滤得黄色固体,加DCM溶解,无水硫酸钠干燥,减压浓缩。经柱层析(DCM/MeOH洗脱)得黄色固体4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)-2-氟苯基)哌嗪-1-羧酸叔丁酯1.7g,收率98%。ESI-MS(M+H)+=501.5。合成步骤2:5-((4-(4-((1-(4-(2,4-二氧代四氢嘧啶-1(2H)-基)-3-甲基苯基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(075)
将075-1(100mg,0.25mmol)溶于3mL DCM中,向体系中加入1.5mL三氟乙酸,室温反应30min。反应结束,减压浓缩得5-((3-氟-4-(哌嗪-1-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺。将所得产物溶于2mL DCM中,向体系中加入中间体29(118mg,0.37mmol),室温搅拌10min,向体系加入醋酸(0.1mL),氰基硼氢化钠(47mg,0.75mmol),室温反应0.5h。反应结束,加水淬灭,DCM萃取,合并有机相,无水硫酸钠干燥,减压浓缩。经柱层析(DCM/MeOH洗脱)得化合物075黄色固体50mg,收率28%。,ESI-MS(M+H)+=700。1H-NMR(400MHz,DMSO-d6)δ11.30(brs,1H),10.25(s,1H),8.35(s,1H),7.62-7.72(m,2H),7.25-7.28(m,1H),7.01-7.06(m,2H),6.76-6.80(m,2H),3.62-3.83(m,7H),3.32-3.48(m,1H),2.98-3.00(m,4H),2.62-2.71(m,4H),2.49-2.52(m,4H),2.20-2.22(m,2H),2.11(s,3H),1.77-1.81(m,2H),1.59-1.67(m,6H),1.16-1.23(m,3H).
实施例45:5-((4-(4-((1-(6-((2,6-二氧代哌啶-3-基)氨基)吡啶-3-基)哌啶-4-基)甲基)哌嗪-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(077)
参考实施例44的合成路线和方法,把合成步骤2中的中间体29替换为中间体36,合成得到目标化合物077,ESI-MS(M+H)+=701。1H-NMR(400MHz,DMSO-d6)δ11.30(brs,1H),10.73(s,1H),8.35(s,1H),7.61-7.72(m,3H),7.19-7.28(m,2H),7.01-7.04(m,1H),6.51-6.53(m,1H),6.37-6.39(m,1H),4.60-4.66(m,1H),3.79-3.83(m,4H),3.34-3.36(m,3H),2.97-3.00(m,4H),2.68-2.77(m,1H),2.51-2.54(m,3H),2.20-2.22(m,2H),1.93-2.10(m,3H),1.75-1.81(m,2H),1.58-1.67(m,6H),1.22-1.26(m,5H).
实施例46:5-((4-(4-((4-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)哌嗪-1-基)甲基)哌啶-1-基)-3-氟苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(044)
参考实施例44合成步骤2的合成路线和方法,把075-1替换为中间体16,把中间体29替换为中间体25,合成得到化合物044黄色固体40mg,收率15%。ESI-MS(M+H)+=754。1H-NMR(400MHz,CCl3D)δ10.85(brs,1H),8.04(brs,1H),7.69-7.70(m,2H),7.60-7.65(m,1H),7.28-7.29(m,1H),7.16-7.19(m,1H),7.05-7.08(m,1H),6.92-6.96(m,1H),5.38(brs,1H),4.92-4.97(m,1H),3.41-3.47(m,6H),2.59-2.92(m,9H),2.29-2.31(m,2H),2.11-2.17(m,3H),1.87-2.01(m,2H),1.65-1.74(m,8H),1.29-1.46(m,3H).
参考实施例44-46的合成路线和方法,合成得到如下目标化合物:
实施例87:5-((4-(1-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-羰基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(055)
合成步骤1:4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-羧酸叔丁酯(055-1)
参考实施例44合成步骤1的合成路线和方法,把中间体4替换为中间体2,合成得到4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-羧酸叔丁酯。ESI-MS(M+H)+=482。
合成步骤2:5-((4-(1-(1-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)吡咯烷-3-羰基)哌啶-4-基)苯基)氨基)-3-(哌啶-1-基)-1,2,4-三嗪-6-甲酰胺(055)
将055-1溶于3mL DCM中,向体系中加入1.5mL三氟乙酸,室温反应30min。反应结束,将所得产物(102mg,0.27mmol)溶于5mL DMF中,向体系中依次加入中间体24(100mg,0.27mmol)、HATU(112mg,0.29mmol)、TEA(81mg,0.80mmol),于30℃反应2h,反应结束。加水淬灭,DCM萃取三次,合并有机相,饱和氯化铵水溶液洗涤有机相,无水硫酸钠干燥,减压浓缩,经柱层析得到化合物055固体60mg,收率30%,ESI-MS(M+H)+=735。
参考实施例87的合成路线和方法,合成得到如下化合物:
实施例94:(3-(5-(3-((4-(4-((6-氨基甲酰基-3-(哌啶-1-基)-1,2,4-三嗪-5-基)氨基)苯基)哌啶-1-基)甲基)吡咯烷-1-基)-1,3-二氧代异吲哚啉-2-基)-2,6-二氧代哌啶-1-基)新戊酸甲酯(062)
将化合物001(100mg,0.12mmol)溶于2mL DMF中,向体系中依次加入碳酸铯(46mg,0.14mmol)、新戊酸氯甲基酯(18mg,0.12mmol),于室温反应12h。反应结束,加水淬灭,EA萃取三次,合并有机相,无水硫酸钠干燥,减压浓缩,得化合物062黄色固体30mg,收率:26%。ESI-MS(M+H)+=835。1H-NMR(400MHz,CDCl3)δ10.89(brs,1H),7.60-7.70(m,4H),7.23-7.24(m,2H),6.96-6.97(m,1H),6.68-6.71(m,1H),5.79-5.84(m,2H),5.40(brs,1H),4.97-5.01(m,1H),3.86-3.95(m,4H),3.44-3.61(m,2H),3.19-3.23(m,1H),2.99-3.03(m,2H),2.79-2.86(m,2H),2.44-2.51(m,3H),2.03-2.24(m,5H),1.70-1.85(m,10H),1.25-1.32(m,3H),1.18(s,9H).
参考实施例94的合成路线和方法,合成得到如下目标化合物:
实施例106.BTK降解活性测试
Mino细胞系细胞50~100万/孔种于6孔板中。化合物稀释到不同浓度,加入到板中,孵育24-72小时后,收取细胞。裂解细胞后,用BCA试剂盒测定各孔总蛋白浓度。使用Westernblot或Elisa法测定BTK的量。
表1化合物的BTK降解活性结果
注A:DC50<10nM
化合物a来自专利WO2021113557A1中的Compound 149;
化合物b来自专利WO2021113557A1中的Compound 44;
本发明的化合物对BTK具有降解作用。
实施例107.肿瘤细胞增殖抑制活性测试
通过测定化合物对OCI-LY10和Mino细胞增殖的抑制作用,检测化合物对抗肿瘤药效。OCI-LY10和Mino细胞培养于含10%胎牛血清的RPMI-1640培养基中。消化细胞,将细胞按OCI-LY10和Mino 10000/孔;的细胞浓度接种于96孔板,3 7℃,5%CO2孵育过夜。9 6孔板中加入不同浓度(1000nM,4倍稀释,8个点)的化合物于37℃,5%CO2孵育72小时或7day后每孔加入20uL MTS。孵育2h后,每孔加入25μl10%SDS终止反应。用酶标仪测量490nm和650nm处的吸收。用GraphPad Prism 5.0计算IC50。
表2本发明化合物对Mino肿瘤细胞增殖抑制活性
化合物编号 | Mino IC50(nM) | 化合物编号 | Mino IC50(nM) |
001 | 5.50 | 044 | 3.46 |
004 | 1.15 | 045 | 3.91 |
005 | 2.47 | 050 | 6.05 |
007 | 5.31 | 075 | 1.42 |
011 | 4.20 | 082 | 2.30 |
012 | 1.22 | 084 | 3.30 |
013 | 3.37 | 087 | 4.31 |
014 | 4.14 | 090 | 1.94 |
016 | 1.45 | 092 | 3.28 |
019 | 2.13 | 098 | 3.11 |
023 | 6.75 | 100 | 3.83 |
033 | 9.10 | 化合物a | 10.56 |
表3本发明化合物对OCI-ly10肿瘤细胞增殖抑制活性
表2和表3表明,本发明的化合物对肿瘤细胞具有明显增殖抑制活性。
实施例108.肝微粒体代谢稳定性
在冰浴下,将人、小鼠肝微粒1mg加入到PBS(1mL)缓冲液,再加入NADPH(20μL),在37℃下孵育5min,加入待测试化合物10μL,用移液枪吸打多次,分成3份,每份330μL。然后分别在0,15、30、60、120min取点。每次用移液枪取出10μL溶液加入到490μL含有内标化合物的溶液中,涡旋后置于冰上,后继续另一个时间点的取样。所有样品在10000rpm下离心10min,取上清液进行LC/MS测试,通过峰面积计算化合物在肝微粒体中的代谢情况。
表4化合物对肝微粒代谢稳定性的测试
由表4可知:本发明的化合物具有较好的代谢稳定性。
实施例109.小鼠吸收试验
实验方法:以小鼠为实验动物,灌胃给药10mg/kg(5%DMSO+5%Solutol+90%生理盐水)。灌胃给药的取血时间点为0.25、0.5、1、2、4、6、8、24h小时。取全血0.3ml,离心后取血浆0.1ml采用LC-MS进行分析。
表5本发明化合物的小鼠吸收结果
编号 | DNAUC |
001 | 2300 |
002 | 2223 |
003 | 1648 |
007 | 1955 |
044 | 1941 |
045 | 1686 |
046 | 1867 |
化合物b | 1088 |
注:DNAUC表示AUC(h*ng/mL)/剂量(mg/kg)。
由表5可知,本发明的化合物在小鼠中具有较好的口服吸收。
实施例110.大鼠吸收试验
以SD大鼠为实验动物,灌胃给药10mg/kg(5%DMSO+5%Solutol+90%生理盐水)。灌胃给药的取血时间点为0.25、0.5、1、2、4、6、8、24h小时。取全血0.3ml,离心后取血浆0.1ml采用LC-MS进行分析。
表6本发明化合物的大鼠吸收结果
编号 | DNAUC |
002 | 252 |
003 | 456 |
045 | 716 |
075 | 1125 |
077 | 285 |
079 | 6611 |
081 | 372 |
085 | 579 |
化合物a | 164 |
注:DNAUC表示AUC(h*ng/mL)/剂量(mg/kg)。
由表6可知,本发明的化合物在大鼠中具有较好的口服吸收。
实施例111.体内抗肿瘤药效
采用NOD/SCID小鼠皮下接种OCL-LY10细胞建立肿瘤模型,当肿瘤长至100mm3左右分组给药,给药方式如下:A组control组灌胃相应体积的CMC-Na溶液;B组灌胃给予3mg/kg受试化合物;C组灌胃给予10mg/kg受试化合物;D组灌胃给予30mg/kg受试化合物;每周两次秤量老鼠体重和肿瘤大小变化,3周后,用颈椎脱臼法处死小鼠,考察了化合物对OCL-LY10小鼠移植瘤的药效。
Claims (13)
1.一种化合物,其特征在于,具有通式(I)所示的结构:
或其立体异构体,或其立体异构体混合物,或其药学上可接受的盐,前药;
其中:
L选自:连接环A和E3的化学基团或化学键;
E3选自:E3泛素连接酶配体;
环A选自:3-12元杂环、6-10元芳环、5-12元杂芳环,3-12元环烷、4-12元环炔、3-12元环烯,其中所述的杂环、杂芳环中具有1-3个独立选自N、O或S的杂原子;
R2选自:H、卤素、氰基、C1-C6烷基、C1-C6卤代烷基、C3-C8环烷基、C1-C4烷氧基、C3-C8环烷氧基、C3-C8杂环基、C1-C4烷氨基、-COOH、-NH2、OH、NO2;
n选自:0、1、2、3、4;
Y1选自:N、CR4;
Y2选自:N、CR5;
Y3选自:N、CR5;
R4选自:卤素、C1-C4烷基、C3-C8环烷基、C1-C4卤代烷基、C3-C8卤代环烷基、C1-C4烷氧基、氨基、羧基、羟基、氰基;
R5选自:H、卤素、C1-C4烷基、C3-C8环烷基、C1-C4卤代烷基、C3-C8卤代环烷基、C1-C4烷氧基、氨基、羧基、羟基、氰基;
R3选自:H、C1-C8烷基、C1-C6卤代烷基、C3-C8烯烃、C3-C8炔烃、环烷基、杂环基、芳基;
R1选自:NR6R7、OR6、SR6、-C(O)R6、-C(O)OR6、-C(O)NR6R7、OC(O)R6、OC(O)NR6R7、S(O)R6、S(O)(=NH)R6、S(O)2NR6R7、N(R6)C(O)R7、N(R6)C(O)OR7、C1-C8烷基、3-12元杂环、5-6元杂芳环、C3-C8环烷基、芳环基,其中所述的烷基、杂环、杂芳环、环烷基、芳环基可进一步被一个或者多个选自R8的取代基取代;
R8选自:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;其中所述的烷基、烷氧基、环烷基可进一步被一个或者多个取代基取代,取代基包括:H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基;
R6、R7各自独立的选自H、C1-C8烷基、胺烷基、羟烷基、C3-C8环烷基、杂环基、芳环基、杂芳基;所述的烷基、胺烷基、羟烷基、环烷基、杂环基、芳环基、杂芳基可进一步被一个或者多个取代基取代,取代基包括H、卤素、羟基、氨基、氰基、氧代、羧基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C3-C8环烷基、-C(O)Ra、-C(O)ORa、-C(O)NRaRb、ORa、OC(O)Ra、OC(O)NRaRb、SRa、S(O)Ra、S(O)(=NH)Ra、S(O)2NRaRb、NRaRb、N(Ra)C(O)Rb、N(Ra)C(O)ORb、N(Rc)C(O)NRaRb、-N(Ra)S(O)2Rb、-N(Ra)S(O)2NRbRc;
Ra、Rb、Rc各自独立的选自H、卤素、烷基、氨基、羟基、氰基、C3-C8环烷基、烷氨基、烷氧基。
2.根据权利要求1所述的化合物,其特征在于:
Y1选自:N;
Y2选自:N;
Y3选自:N。
8.一种药物组合物,其特征在于,包括如权利要求1至7中任意一项所述的化合物中的一种或多种。
9.一种如权利要求1至7中任意一项所述的化合物或权利要求8所述组合物在制备单独或与其他药物联合应用治疗从布鲁顿酪氨酸激酶活性的抑制中获益的疾病、障碍或病症药物中的应用。
10.如权利要求9所述的应用,其特征在于,所述的疾病、障碍或病症为从抑制布鲁顿酪氨酸激酶突变中获益的疾病、障碍或病症。
11.如权利要求9所述的应用,其特征在于,所述疾病选自B细胞或浆细胞增殖性疾病和自身免疫性疾病中的一种或多种。
12.如权利要求11所述的应用,其特征在于,所述B细胞或浆细胞增殖性疾病包括弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、慢性淋巴细胞淋巴瘤、慢性淋巴细胞白血病、B细胞前淋巴细胞性白血病、淋巴浆细胞淋巴瘤/瓦尔登斯特伦巨球蛋白血症、脾边缘区淋巴瘤、浆细胞性骨髓瘤、浆细胞瘤、结外边缘区B细胞淋巴瘤、淋巴结边缘区B细胞淋巴瘤、外套细胞淋巴瘤、纵膈(胸腺)大B细胞淋巴瘤、血管内大B细胞淋巴瘤、原发性渗出性淋巴瘤、伯基特淋巴瘤/白血病或淋巴瘤样肉芽肿病、多发性骨髓瘤。
13.如权利要求11所述的应用,其特征在于,所述自身免疫性疾病包括炎性肠病、关节炎、狼疮、类风湿性关节炎、银屑病性关节炎、骨关节炎、斯蒂尔病、青少年关节炎、糖尿病、重症肌无力症、桥本甲状腺炎奥德甲状腺炎、格雷夫斯氏病、类风湿性关节炎综合征、多发性硬化症、传染性神经元炎、急性播散性脑脊髓炎、阿狄森病、视性眼阵挛-肌阵挛综合征、强制性脊椎炎、抗磷脂抗体综合征、再生障碍性贫血、自身免疫性肝炎、乳糜泻、古德帕斯彻综合征、免疫性血小板减少性紫癜、视神经炎、硬皮病、原发性胆汁性肝硬化、莱特尔综合征、高安动脉炎、颞动脉炎、温型自身免疫性溶血性贫血、韦格纳肉芽肿病、银屑病、全身脱毛、贝赫切特病、慢性疲劳、家族性自主神经功能异常、子宫内膜异位、间质性膀胱炎、神经肌强直、硬皮病或外阴痛和慢性移植物抗宿主病。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111383481 | 2021-11-22 | ||
CN2021113834815 | 2021-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116143757A true CN116143757A (zh) | 2023-05-23 |
Family
ID=86351473
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211467110.XA Pending CN116143757A (zh) | 2021-11-22 | 2022-11-22 | 一种可降解btk激酶的多功能化合物、组合物及应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116143757A (zh) |
WO (1) | WO2023088477A1 (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105960404A (zh) * | 2013-12-05 | 2016-09-21 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶的抑制剂 |
CN107709315A (zh) * | 2015-06-02 | 2018-02-16 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶的抑制剂 |
WO2021113557A1 (en) * | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
CN113412259A (zh) * | 2018-10-15 | 2021-09-17 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105777759B (zh) * | 2016-04-29 | 2018-01-26 | 杭州和正医药有限公司 | 一种布鲁顿酪氨酸激酶抑制剂 |
GB201614134D0 (en) * | 2016-08-18 | 2016-10-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CN110483521B (zh) * | 2018-05-14 | 2022-06-07 | 杭州和正医药有限公司 | 一种可逆共价布鲁顿酪氨酸激酶抑制剂、药物组合物及其应用 |
CN111285851A (zh) * | 2020-03-23 | 2020-06-16 | 沈阳药科大学 | 靶向降解黏着斑激酶的化合物及其在医药上的应用 |
-
2022
- 2022-11-22 WO PCT/CN2022/133404 patent/WO2023088477A1/zh unknown
- 2022-11-22 CN CN202211467110.XA patent/CN116143757A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105960404A (zh) * | 2013-12-05 | 2016-09-21 | 药品循环有限责任公司 | 布鲁顿氏酪氨酸激酶的抑制剂 |
CN107709315A (zh) * | 2015-06-02 | 2018-02-16 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN113412259A (zh) * | 2018-10-15 | 2021-09-17 | 紐力克斯治疗公司 | 通过泛素蛋白酶体途径降解btk的双官能化合物 |
WO2021113557A1 (en) * | 2019-12-04 | 2021-06-10 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
Non-Patent Citations (1)
Title |
---|
房宜嘉;胡媛媛;凌兰兰;陈月;史玉叶;张莉;王春玲;于亮;: "Bruton酪氨酸激酶泛素化调节的研究", 中国实验血液学杂志, no. 05, pages 296 - 302 * |
Also Published As
Publication number | Publication date |
---|---|
WO2023088477A1 (zh) | 2023-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018222943B2 (en) | Heterocyclic compounds useful as PDK1 inhibitors | |
AU2016228660B2 (en) | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug | |
JP7392164B2 (ja) | ヘテロアリール誘導体、その製造方法およびその使用 | |
AU2024200566A1 (en) | Pyridazinones as PARP7 inhibitors | |
CN112707893B (zh) | 作为usp30抑制剂的1-氰基吡咯烷化合物 | |
JP2023011889A (ja) | Shp2阻害剤として有用な新規な複素環式誘導体 | |
ES2902676T3 (es) | Aminotriazolopiridinas como inhibidores de cinasa | |
CN112778276A (zh) | 作为shp2抑制剂的化合物及其应用 | |
AU2018237123B2 (en) | Bruton's tyrosine kinase inhibitors | |
CN115461334A (zh) | 一种苯并咪唑类衍生物及其制备方法和医药用途 | |
EP3784671B1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
KR20150028999A (ko) | 5-아자인다졸 화합물 및 이의 사용 방법 | |
CN105732637B (zh) | 杂芳化合物及其在药物中的应用 | |
EP4155308A1 (en) | Rock inhibitor, and preparation method therefor and use thereof | |
EP3741752A1 (en) | Tam family kinase /and csf1r kinase inhibitor and use thereof | |
WO2019074809A1 (en) | INDAZOLYL-SPIRO [2.2] PENTANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
CA3130245A1 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
WO2022266258A1 (en) | Compounds and methods for the targeted degradation of irak-4 | |
KR20210105375A (ko) | Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도 | |
JP2024505711A (ja) | 窒素含有多環式縮合環系化合物、その医薬組成物、製造方法及び用途 | |
AU2019379213B2 (en) | Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor | |
JP2023513333A (ja) | キノリニル基ホスフィンオキシド化合物、並びにその組成物及び使用 | |
KR20180124737A (ko) | 피라졸로 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암, 자가면역질환 및 뇌질환의 예방 또는 치료용 약학적 조성물 | |
CN116143757A (zh) | 一种可降解btk激酶的多功能化合物、组合物及应用 | |
JP2022534434A (ja) | P2x3阻害剤としてのピリドピリミジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |